<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Tofacitinib: Pediatric drug information</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Tofacitinib: Pediatric drug information</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="drugTitle">Tofacitinib: Pediatric drug information</div><div class="clear"></div><div id="topicText">(For additional information <a class="drug drug_general" data-topicid="87040" href="/d/html/87040.html" rel="external">see "Tofacitinib: Drug information"</a> and <a class="drug drug_patient" data-topicid="87670" href="/d/html/87670.html" rel="external">see "Tofacitinib: Patient drug information"</a>)<br/><br/>For abbreviations, symbols, and age group definitions used in Lexicomp (<a class="graphic graphic_table" href="/d/html/57469.html" rel="external">show table</a>)<div class="block black-box-warn drugH1Div" id="F15578463"><span class="drugH1">ALERT: US Boxed Warning</span>
<div class="collapsible">
<span class="collapsible-title">Serious infections:</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">Patients treated with tofacitinib are at increased risk of developing serious infections that may lead to hospitalization or death. Most patients who developed these infections were taking concomitant immunosuppressants, such as methotrexate or corticosteroids.</p>
<p style="text-indent:-2em;margin-left:2em;">If a serious infection develops, interrupt tofacitinib until the infection is controlled.</p>
<p style="text-indent:-2em;margin-left:2em;">Reported infections include:</p>
<p style="text-indent:-2em;margin-left:4em;">• Active tuberculosis (TB), which may present with pulmonary or extrapulmonary disease. Patients should be tested for latent TB before tofacitinib use and during therapy. Treatment for latent infection should be initiated prior to tofacitinib use.</p>
<p style="text-indent:-2em;margin-left:4em;">• Invasive fungal infections, including cryptococcosis and pneumocystosis. Patients with invasive fungal infections may present with disseminated rather than localized disease.</p>
<p style="text-indent:-2em;margin-left:4em;">• Bacterial, viral (including herpes zoster), and other infections due to opportunistic pathogens.</p>
<p style="text-indent:-2em;margin-left:2em;">The risks and benefits of treatment with tofacitinib should be carefully considered prior to initiating therapy in patients with chronic or recurrent infection.</p>
<p style="text-indent:-2em;margin-left:2em;">Patients should be closely monitored for the development of signs and symptoms of infection during and after treatment with tofacitinib, including the possible development of TB in patients who tested negative for latent TB infection prior to initiating therapy.</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">Mortality:</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">In a large, randomized, postmarketing safety study in rheumatoid arthritis (RA) patients ≥50 years of age with ≥1 cardiovascular risk factor comparing tofacitinib 5 mg twice a day or tofacitinib 10 mg twice a day to tumor necrosis factor (TNF) blockers, a higher rate of all-cause mortality, including sudden cardiovascular death, was observed with tofacitinib 5 mg twice a day or tofacitinib 10 mg twice a day. Tofacitinib 10 mg twice daily (or tofacitinib XR 22 mg once daily) dosage is not recommended for the treatment of RA or psoriatic arthritis (PsA).</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">Malignancies:</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">Malignancies, including lymphomas and solid tumors, have occurred in patients treated with tofacitinib and other Janus kinase inhibitors used to treat inflammatory conditions. In RA patients, a higher rate of malignancies (excluding non-melanoma skin cancer [NMSC]) was observed in patients treated with tofacitinib 5 mg twice a day or tofacitinib 10 mg twice a day compared TNF blockers.</p>
<p style="text-indent:-2em;margin-left:2em;">Lymphomas and lung cancers were observed at a higher rate in patients treated with tofacitinib 5 mg twice a day or tofacitinib 10 mg twice a day in RA patients compared to those treated with TNF blockers. Patients who are current or past smokers are at additional increased risk.</p>
<p style="text-indent:-2em;margin-left:2em;">Epstein-Barr virus-associated posttransplant lymphoproliferative disorder has been observed at an increased rate in renal transplant patients treated with tofacitinib and concomitant immunosuppressive medications.</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">Major adverse cardiovascular events:</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">RA patients ≥50 years of age with ≥1 cardiovascular risk factor, treated with tofacitinib 5 mg twice daily or tofacitinib 10 mg twice daily, had a higher rate of major adverse cardiovascular events (defined as cardiovascular death, myocardial infarction, and stroke), compared to those treated with TNF blockers. Patients who are current or past smokers are at additional increased risk. Discontinue tofacitinib in patients that have experienced a myocardial infarction or stroke.</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">Thrombosis:</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">Thrombosis, including pulmonary embolism, deep venous thrombosis, and arterial thrombosis, have occurred in patients treated with tofacitinib and other Janus kinase inhibitors used to treat inflammatory conditions. Many of these events were serious and some resulted in death. RA patients ≥50 years of age with ≥1 cardiovascular risk factor treated with tofacitinib 5 mg twice daily or tofacitinib 10 mg twice daily compared to TNF blockers had an observed increase in incidence of these events. Avoid tofacitinib in patients at risk. Discontinue tofacitinib and promptly evaluate patients with symptoms of thrombosis.</p></div>
</div>
</div>
<div class="visuallyHidden drugH1Div" id="formulinkBodyPlaceholder"><span class="drugH1"></span></div>
<div class="list ubnlist drugH1Div drugBrandNames" id="F54979820"><span class="drugH1">Brand Names: US</span>
<ul>
<li>Xeljanz;</li>
<li>Xeljanz XR</li></ul></div>
<div class="list canbnlist drugH1Div drugBrandNames" id="F52871528"><span class="drugH1">Brand Names: Canada</span>
<ul>
<li>AURO-Tofacitinib;</li>
<li>JAMP-Tofacitinib;</li>
<li>PMS-Tofacitinib;</li>
<li>TARO-Tofacitinib;</li>
<li>Xeljanz;</li>
<li>Xeljanz XR</li></ul></div>
<div class="list_set htclist drugH1Div drugBrandNames" id="F54975483"><span class="drugH1">Therapeutic Category</span>
<ul>
<li>
<span class="list-set-name">Antirheumatic Miscellaneous</span>;</li>
<li>
<span class="list-set-name">Antirheumatic, Disease Modifying</span>;</li>
<li>
<span class="list-set-name">Janus Associated Kinase Inhibitor</span></li></ul></div>
<div class="block dop drugH1Div" id="F54975488"><span class="drugH1">Dosing: Pediatric</span>
<p style="text-indent:0em;display:inline">
<b>Note:</b> Oral solution and extended-release tablets are not bioequivalent and should not be substituted on a mg:mg basis; oral solution and immediate-release tablet may be converted mg:mg (5 mg oral solution may be switched to 5 mg immediate-release tablet). Assess baseline CBC; do not initiate therapy in patients with an absolute lymphocyte count &lt;500 cells/mm<sup>3</sup>, ANC &lt;1,000 cells/mm<sup>3</sup>, or hemoglobin &lt;9 g/dL.</p>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="47bb15f6-50cb-4ceb-83b6-0323e73883c3">Juvenile idiopathic arthritis, polyarticular course</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Juvenile idiopathic arthritis, polyarticular course:</b> Children ≥2 years weighing ≥10 kg and Adolescents: Oral:</p>
<p style="text-indent:-2em;margin-left:4em;">10 to &lt;20 kg: Oral solution (1 mg/mL): 3.2 mg twice daily.</p>
<p style="text-indent:-2em;margin-left:4em;">20 to &lt;40 kg: Oral solution (1 mg/mL): 4 mg twice daily.</p>
<p style="text-indent:-2em;margin-left:4em;">≥40 kg: Oral solution (1 mg/mL) or immediate-release tablet: 5 mg twice daily.</p></div>
</div>
<p style="text-indent:-2em;margin-left:2em;">
<b>Dosage adjustment for concomitant therapy:</b> Significant drug interactions exist, requiring dose/frequency adjustment or avoidance. Consult drug interactions database for more information.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Dosage adjustment for toxicity:</b> Children ≥2 years and Adolescents: Oral: Oral solution, immediate-release tablets:</p>
<p style="text-indent:-2em;margin-left:4em;">Infection: If a patient develops a serious infection, interrupt treatment until the infection is controlled.</p>
<p style="text-indent:-2em;margin-left:4em;">Anemia (hemoglobin &lt;8 g/dL or decrease &gt;2 g/dL): Interrupt therapy until hemoglobin values have normalized.</p>
<p style="text-indent:-2em;margin-left:4em;">Lymphopenia (lymphocytes &lt;500 cells/mm<sup>3</sup>) confirmed by repeat evaluation: Discontinue therapy.</p>
<p style="text-indent:-2em;margin-left:4em;">Neutropenia:</p>
<p style="text-indent:-2em;margin-left:6em;">ANC between 500 to 1,000 cells/mm<sup>3</sup>: Interrupt therapy until ANC &gt;1,000 cells/mm<sup>3</sup>.</p>
<p style="text-indent:-2em;margin-left:6em;">ANC &lt;500 cells/mm<sup>3</sup>: Discontinue therapy.</p></div>
<div class="block dorp drugH1Div" id="F54975489"><span class="drugH1">Dosing: Kidney Impairment: Pediatric</span>
<p style="text-indent:-2em;margin-left:2em;">Children ≥2 years and Adolescents: Oral: Oral solution, immediate-release tablets:</p>
<p style="text-indent:-2em;margin-left:4em;">Mild kidney impairment: No adjustment necessary.</p>
<p style="text-indent:-2em;margin-left:4em;">Moderate to severe kidney impairment: Reduce dose frequency to once daily.</p>
<p style="text-indent:-2em;margin-left:4em;">Hemodialysis: Administer dose after dialysis session on dialysis days; if dose administered before session, a supplemental dose post-dialysis is not recommended.</p></div>
<div class="block dohp drugH1Div" id="F54975490"><span class="drugH1">Dosing: Hepatic Impairment: Pediatric</span>
<p style="text-indent:-2em;margin-left:2em;">Children ≥2 years and Adolescents: Oral: Oral solution, immediate-release tablet:</p>
<p style="text-indent:-2em;margin-left:4em;">Mild hepatic impairment: No adjustment necessary.</p>
<p style="text-indent:-2em;margin-left:4em;">Moderate hepatic impairment: Reduce dose frequency to once daily.</p>
<p style="text-indent:-2em;margin-left:4em;">Severe hepatic impairment: Use is not recommended.</p></div>
<div class="block doa drugH1Div" id="F15897300"><span class="drugH1">Dosing: Adult</span><p>(For additional information <a class="drug drug_general" data-topicid="87040" href="/d/html/87040.html" rel="external">see "Tofacitinib: Drug information"</a>)</p>
<p style="text-indent:0em;display:inline">
<b>Note:</b> ER tablets and oral solution are not interchangeable or substitutable. When transitioning from IR tablet to ER tablet, begin ER tablet the day following the last dose of IR tablet. Do not initiate therapy in patients with an absolute lymphocyte count &lt;500 cells/mm<sup>3</sup>, ANC &lt;1,000 cells/mm<sup>3</sup>, or hemoglobin &lt;9 g/dL.</p>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="62637659-f98d-4a3f-aec5-dbd1f84dc2b2">Ankylosing spondylitis</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Ankylosing spondylitis: Oral: </b></p>
<p style="text-indent:-2em;margin-left:4em;">IR tablet: 5 mg twice daily.</p>
<p style="text-indent:-2em;margin-left:4em;">ER tablet: 11 mg once daily.</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="894e2a7e-3fff-4cb6-8ddb-f11aa30fb548">COVID-19, hospitalized patients</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>COVID-19, hospitalized patients (alternative agent) (off-label use):</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Note:</b> For use only as an alternative to baricitinib, for hospitalized patients with significant oxygen requirements (eg, high-flow oxygen, noninvasive ventilation, mechanical ventilation, extracorporeal membrane oxygenation) and those with lower but increasing oxygen requirements and evidence of systemic inflammation (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Bhimraj.1','lexi-content-ref-NIH.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Bhimraj.1','lexi-content-ref-NIH.1'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Oral:</b> IR tablet: 10 mg twice daily, as part of an appropriate combination regimen, for 14 days or until hospital discharge, whichever is earlier (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-34133856','lexi-content-ref-NIH.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-34133856','lexi-content-ref-NIH.1'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="9c51dc6e-ca0a-48cc-bfad-6cb5d9403c14">Psoriasis</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Psoriasis (off-label): Oral:</b> IR tablet: 5 to 10 mg twice daily (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-32119894','lexi-content-ref-26051365','lexi-content-ref-22924949','lexi-content-ref-26149717']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-32119894','lexi-content-ref-26051365','lexi-content-ref-22924949','lexi-content-ref-26149717'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="1bfcea56-f4f1-4785-9277-8d2c90e99a99">Psoriatic arthritis</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Psoriatic arthritis (use in combination with nonbiologic disease-modifying antirheumatic drugs):</b>
<b>Oral:</b></p>
<p style="text-indent:-2em;margin-left:4em;">IR tablet: 5 mg twice daily.</p>
<p style="text-indent:-2em;margin-left:4em;">ER tablet: 11 mg once daily.</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="32775de1-c27b-4d28-84e6-04adfdee9a40">Rheumatoid arthritis</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Rheumatoid arthritis:</b>
<b></b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Note:</b> For use as adjunctive therapy with nonbiologic disease-modifying antirheumatic drugs (DMARDs) in patients who have not met treatment goals despite maximally tolerated methotrexate therapy; may also be used off label as an alternative to methotrexate in DMARD-naive patients with moderate to high disease activity (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-34101387']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-34101387'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Oral: </b></p>
<p style="text-indent:-2em;margin-left:6em;">IR tablet: 5 mg twice daily.</p>
<p style="text-indent:-2em;margin-left:6em;">ER tablet: 11 mg once daily.</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="e147f438-ac03-44c7-98c9-bf0acd598ea0">Ulcerative colitis</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Ulcerative colitis (alternative agent): </b>
<b>Oral:</b></p>
<p style="text-indent:-2em;margin-left:4em;">IR tablet:</p>
<p style="text-indent:-2em;margin-left:6em;">Induction: 10 mg twice daily for at least 8 weeks; based on therapeutic response, may continue 10 mg twice daily for a maximum of 16 weeks or transition to maintenance dose. Discontinue therapy if inadequate response achieved after 16 weeks using 10 mg twice daily.</p>
<p style="text-indent:-2em;margin-left:6em;">Maintenance: 5 mg twice daily; if patient experiences loss of response on 5 mg twice daily, then use 10 mg twice daily after assessing the benefits and risks and use for the shortest duration; use lowest effective dose to maintain response.</p>
<p style="text-indent:-2em;margin-left:4em;">ER tablet:</p>
<p style="text-indent:-2em;margin-left:6em;">Induction: 22 mg once daily for at least 8 weeks; based on therapeutic response, may continue 22 mg once daily for a maximum of 16 weeks or transition to maintenance dose. Discontinue therapy if inadequate response achieved after 16 weeks using 22 mg once daily.</p>
<p style="text-indent:-2em;margin-left:6em;">Maintenance: 11 mg once daily; if patient experiences loss of response on 11 mg once daily, then use 22 mg once daily after assessing the benefits and risks and use for the shortest duration; use lowest effective dose to maintain response.</p></div>
</div>
<p style="text-indent:-2em;margin-left:2em;">
<b>Dosage adjustment for concomitant therapy: </b>Significant drug interactions exist, requiring dose/frequency adjustment or avoidance. Consult drug interactions database for more information.</p></div>
<div class="block dora drugH1Div" id="F50991186"><span class="drugH1">Dosing: Kidney Impairment: Adult</span>
<p style="text-indent:-2em;margin-left:2em;">Mild impairment: No dosage adjustment necessary.</p>
<p style="text-indent:-2em;margin-left:2em;">Moderate to severe impairment:</p>
<p style="text-indent:-2em;margin-left:4em;">IR tablet: Reduce dose to 5 mg twice daily (if taking 10 mg twice daily) or 5 mg once daily (if taking 5 mg twice daily).</p>
<p style="text-indent:-2em;margin-left:4em;">ER tablet: Reduce dose to 11 mg once daily (if taking 22 mg once daily) or transition to immediate release 5 mg once daily (if taking 11 mg once daily).</p>
<p style="text-indent:-2em;margin-left:2em;">End-stage renal disease requiring hemodialysis: <b>Note:</b> Administer after dialysis session on dialysis days; if dose given prior to dialysis, supplemental dose is not recommended after dialysis session.</p>
<p style="text-indent:-2em;margin-left:4em;">IR tablet: Reduce dose to 5 mg twice daily (if taking 10 mg twice daily) or 5 mg once daily (if taking 5 mg twice daily).</p>
<p style="text-indent:-2em;margin-left:4em;">ER tablet: Reduce dose to 11 mg once daily (if taking 22 mg once daily) or transition to immediate release 5 mg once daily (if taking 11 mg once daily).</p></div>
<div class="block doha drugH1Div" id="F50988532"><span class="drugH1">Dosing: Hepatic Impairment: Adult</span>
<p style="text-indent:-2em;margin-left:2em;">Mild impairment: No dosage adjustment necessary.</p>
<p style="text-indent:-2em;margin-left:2em;">Moderate impairment:</p>
<p style="text-indent:-2em;margin-left:4em;">IR tablet: Reduce dose to 5 mg twice daily (if taking 10 mg twice daily) or 5 mg once daily (if taking 5 mg twice daily).</p>
<p style="text-indent:-2em;margin-left:4em;">ER tablet: Reduce dose to 11 mg once daily (if taking 22 mg once daily) or transition to immediate release 5 mg once daily (if taking 11 mg once daily).</p>
<p style="text-indent:-2em;margin-left:2em;">Severe impairment: Use is not recommended (has not been studied in patients with severe hepatic impairment or in patients with hepatitis B or hepatitis C viruses).</p></div>
<div class="block arsc drugH1Div" id="F57428945"><span class="drugH1">Adverse Reactions (Significant): Considerations</span>
<div class="collapsible">
<span class="collapsible-title">Bone marrow suppression</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Lymphocytopenia</b> (after an initial <b>lymphocytosis</b>), <b>neutropenia</b>, and <b>anemia </b>have been observed with tofacitinib therapy. <b>Thrombocytopenia</b> has also been reported (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-33080751']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-33080751'])">Ref</a></span>). In an open-label long-term extension study over 9.5 years, potentially life-threatening lymphocytopenia (&lt;500 cells/mm<sup>3</sup>) occurred in ~1% of patients; &lt;1% of these patients developed serious infections. Moderate to severe neutropenia occurred in ~1% and &lt;1% of patients, respectively; no patients developed serious infections (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-30953540']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-30953540'])">Ref</a></span>). In another study, &lt;1% of patients experienced a clinically significant decrease in hemoglobin (defined as a ≥3 g/dL decrease from baseline or hemoglobin ≤7 g/dL) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-28028154']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-28028154'])">Ref</a></span>). Cell counts typically stabilize with continued treatment; for cases requiring discontinuation, partial or complete resolution usually occurred (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-28028154','lexi-content-ref-30953540']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-28028154','lexi-content-ref-30953540'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Mechanism:</i> Dose-related; may impair pro-growth signaling in bone marrow stem cells (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-29622655','lexi-content-ref-28513593','lexi-content-ref-28028154','lexi-content-ref-27905037']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-29622655','lexi-content-ref-28513593','lexi-content-ref-28028154','lexi-content-ref-27905037'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Onset:</i> Delayed. Lymphocytopenia: Increases in lymphocyte counts in the first 3 months, followed by decreases for up to 48 months. Neutropenia: Decreases in the first 24 months (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-28028154','lexi-content-ref-30427585','lexi-content-ref-30953540']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-28028154','lexi-content-ref-30427585','lexi-content-ref-30953540'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Risk factors:</i></p>
<p style="text-indent:-2em;margin-left:6em;">• Higher doses (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-30242639','lexi-content-ref-28028154']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-30242639','lexi-content-ref-28028154'])">Ref</a></span>)</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">Cardiovascular events</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">Data regarding risk of major cardiovascular events (MACE) with tofacitinib are unclear. In a long-term open-label extension study over 9.5 years, the rate of cardiovascular events was low (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-30953540']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-30953540'])">Ref</a></span>). Another study over a median follow-up of 4 years found an increased risk of MACE (including <b>acute myocardial infarction</b> and <b>cerebrovascular accident</b>) in patients ≥50 years of age with rheumatoid arthritis (RA) receiving tofacitinib compared to patients receiving tumor necrosis factor inhibitors (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-35081280']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-35081280'])">Ref</a></span>). Furthermore, a study using a simulated clinical trial cohort with real world data found a small but statistically insignificant increase in cardiovascular outcomes (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-35027405']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-35027405'])">Ref</a></span>). However, in a large registry of patients with RA, the rate of MACE was similar to patients receiving biological disease-modifying drugs (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-33570260']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-33570260'])">Ref</a></span>), and a World Health Organization database also failed to find an association (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-35504889']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-35504889'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Mechanism:</i> Unknown; although, tofacitinib increases lipid levels by reducing cholesterol ester metabolism (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-35081280']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-35081280'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Risk factors:</i></p>
<p style="text-indent:-2em;margin-left:6em;">• Age ≥65 years (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-35081280']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-35081280'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Cardiovascular risk factors (eg, current or former smokers)</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">GI perforation</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Gastrointestinal </b>(GI)<b> perforation</b> has been reported, typically secondary to diverticulitis, and may be life-threatening. Most perforations have occurred in the lower GI tract (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-30806708']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-30806708'])">Ref</a></span>). Incidence was rare in patients with rheumatoid arthritis in long-term studies; lower incidence than tocilizumab but higher incidence than tumor necrosis factor inhibitors (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-33127856','lexi-content-ref-30806708','lexi-content-ref-30953540','lexi-content-ref-27213279']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-33127856','lexi-content-ref-30806708','lexi-content-ref-30953540','lexi-content-ref-27213279'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Onset:</i> Varied; may occur weeks to years after initiation (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-33127856','lexi-content-ref-30806708','lexi-content-ref-24692527','lexi-content-ref-27213279']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-33127856','lexi-content-ref-30806708','lexi-content-ref-24692527','lexi-content-ref-27213279'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Risk factors:</i></p>
<p style="text-indent:-2em;margin-left:6em;">• Older age (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-30806708','lexi-content-ref-27213279']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-30806708','lexi-content-ref-27213279'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Concurrent glucocorticoids (ie, prednisone ≥7.5 mg/day) or nonsteroidal anti-inflammatory drugs (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-33127856','lexi-content-ref-30806708','lexi-content-ref-27213279']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-33127856','lexi-content-ref-30806708','lexi-content-ref-27213279'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• History of diverticulitis/other GI conditions (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-33127856','lexi-content-ref-30806708','lexi-content-ref-27213279']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-33127856','lexi-content-ref-30806708','lexi-content-ref-27213279'])">Ref</a></span>)</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">Hepatic effects</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Increased liver enzymes </b>may occur, which are usually mild and transient and rarely result in dose adjustment or discontinuation (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-33470695','lexi-content-ref-35081280']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-33470695','lexi-content-ref-35081280'])">Ref</a></span>). <b>Hepatotoxicity</b> is rare (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-33470695']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-33470695'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Mechanism:</i> Unknown, dose-related; metabolized in the liver through the CYP 3A4 pathway. Hepatotoxicity may be related to the production of a toxic or immunogenic intermediate (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-33470695']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-33470695'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Risk factors:</i></p>
<p style="text-indent:-2em;margin-left:6em;">• Higher doses (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-35081280']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-35081280'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Concurrent use of conventional synthetic disease modifying antirheumatic drugs (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-30177460']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-30177460'])">Ref</a></span>)</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">Infection</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">Patients receiving tofacitinib are at increased risk for <b>infection </b>(including <b>serious infection</b>), which may result in hospitalization and/or fatality. Infections may present as disseminated (rather than local) disease. Active <b>tuberculosis</b> (including disseminated), invasive <b>fungal infection</b> (including cryptococcosis and pneumocystosis), <b>bacterial infection</b>, <b>viral infection</b>, or other <b>opportunistic infection</b> have been reported. <b>Nasopharyngitis</b>, <b>upper respiratory tract infections</b>, and <b>urinary tract infections</b> are the most common infections (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-30953540']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-30953540'])">Ref</a></span>). Other infections, including <b>appendicitis</b>, <b>cellulitis</b>, <b>diverticulitis of the gastrointestinal tract</b>, <b>herpes zoster infections</b> (including disseminated cutaneous, meningoencephalitis, ophthalmologic) and <b>reactivation of hepatitis B virus </b>have also been reported. One study over a median follow-up of 4 years found an increased risk of infections in patients ≥50 years of age with rheumatoid arthritis (RA) receiving tofacitinib compared to patients receiving tumor necrosis factor inhibitors (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-35081280']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-35081280'])">Ref</a></span>). In additional studies in patients with RA, the incidence of herpes zoster in patients receiving tofacitinib was more than twice that in patients receiving biological disease modifying drugs (DMARDs) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-27113415','lexi-content-ref-33570260']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-27113415','lexi-content-ref-33570260'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Mechanism:</i> Dose-related; may impair lymphocyte function, leading to suppression of immune response and increased risk of infection (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-35194004']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-35194004'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Onset: </i>Delayed; median exposure prior to diagnosis of an opportunistic infection was 8 months (range: ~40 days to ~2 years).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Risk factors:</i></p>
<p style="text-indent:-2em;margin-left:6em;">• Higher doses (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-35081280']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-35081280'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Older age (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-27113415']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-27113415'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Concurrent immunosuppressants (eg, corticosteroids, conventional synthetic DMARDS (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-27113415','lexi-content-ref-30177460']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-27113415','lexi-content-ref-30177460'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Asian ethnicity (for herpes zoster) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-30900375','lexi-content-ref-24692527']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-30900375','lexi-content-ref-24692527'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Females (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-27113415']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-27113415'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Lymphocytopenia (&lt;500 cells/mm<sup>3</sup>) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-30953540']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-30953540'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• History of an opportunistic infection</p>
<p style="text-indent:-2em;margin-left:6em;">• Chronic or recurrent infection</p>
<p style="text-indent:-2em;margin-left:6em;">• Conditions that predispose to infections (eg, advanced or poorly controlled diabetes)</p>
<p style="text-indent:-2em;margin-left:6em;">• Residence/travel in areas of endemic tuberculosis or mycoses (blastomycosis, coccidioidomycosis, histoplasmosis)</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">Malignancy</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Malignant neoplasm</b>, including <b>malignant lymphoma</b> and <b>malignant solid tumor</b>, have occurred in patients treated with tofacitinib and other Janus kinase inhibitors for the treatment of inflammatory conditions. The most common types of malignancy observed were <b>lung carcinoma</b>, <b>malignant neoplasm of the breast</b>, <b>gastric carcinoma</b>, <b>malignant neoplasm of colon or rectum</b>, <b>renal cell carcinoma</b>, <b>prostate carcinoma</b>, <b>malignant lymphoma</b>, <b>pancreatic adenocarcinoma</b>, and <b>malignant melanoma</b>. One study over a median follow-up of 4 years found an increased risk of malignancies in patients ≥50 years of age with rheumatoid arthritis (RA) receiving tofacitinib compared to patients receiving tumor necrosis factor inhibitors (TNFi) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-35081280']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-35081280'])">Ref</a></span>). In contrast, no increase in risk of malignancies in general or of any specific type was detected compared to patients with RA receiving conventional synthetic disease modifying drugs (DMARDs) or with TNFi in earlier meta-analyses of randomized clinical trials (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-28284845','lexi-content-ref-33910632','lexi-content-ref-32906027']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-28284845','lexi-content-ref-33910632','lexi-content-ref-32906027'])">Ref</a></span>). In two large registries of patients with RA, the rate of malignancy in patients receiving tofacitinib was similar to patients receiving biological DMARDs or with TNFi (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-35643956','lexi-content-ref-33570260']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-35643956','lexi-content-ref-33570260'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Mechanism:</i> Not clearly established; may inhibit immunosurveillance to malignancy (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-33910632']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-33910632'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Risk factors:</i></p>
<p style="text-indent:-2em;margin-left:6em;">• Age ≥65 years (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-35081280']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-35081280'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Current or former smoker</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">Thrombosis</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Thrombosis</b>, including <b>arterial thrombosis</b>, <b>deep vein thrombosis</b>, and <b>pulmonary embolism</b>, have occurred in patients treated with tofacitinib and other Janus kinase (JAK) inhibitors used to treat inflammatory conditions. One study over a median follow-up of 4 years found an increased risk of <b>venous thrombosis</b> and pulmonary embolism in patients ≥50 years of age with rheumatoid arthritis (RA) receiving tofacitinib compared to patients receiving tumor necrosis factor inhibitors (TNFi) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-35081280']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-35081280'])">Ref</a></span>). However, in multiple large registries of patients with RA and other patients, the rate of thrombotic events with tofacitinib was low and similar to patients who used biological disease modifying drugs or TNFi (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-33752237','lexi-content-ref-30552833','lexi-content-ref-33570260','lexi-content-ref-32759265']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-33752237','lexi-content-ref-30552833','lexi-content-ref-33570260','lexi-content-ref-32759265'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Mechanism:</i> Dose-related; JAK inhibition may affect a variety of pathways affecting endothelial activation and platelet aggregation (Kotyla 2021). Tofacitinib may also have off-target effects not related to JAK inhibition (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-35551258']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-35551258'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Risk factors:</i></p>
<p style="text-indent:-2em;margin-left:6em;">• Higher doses (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-35081280']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-35081280'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Cardiovascular or venous thromboembolic risk factors (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-32759265']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-32759265'])">Ref</a></span>)</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">Tuberculosis</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">Active <b>tuberculosis</b> (TB), which may present with pulmonary or extrapulmonary disease, has been reported. One study over a median follow-up of 4 years found an increased risk of TB in patients ≥50 years of age with rheumatoid arthritis (RA) receiving tofacitinib compared to patients receiving tumor necrosis factor inhibitors (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-35081280']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-35081280'])">Ref</a></span>). In a meta-analysis of randomized clinical trials, the risk of TB in patients receiving tofacitinib at any dose was higher versus placebo but not statistically significant (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-35194004']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-35194004'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Mechanism:</i> Dose-related; may impair lymphocyte function, leading to suppression of immune response and increased risk of infection (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-35194004']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-35194004'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Risk factors:</i></p>
<p style="text-indent:-2em;margin-left:6em;">• Higher dose (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-35194004']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-35194004'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Residence in an area with high TB prevalence</p>
<p style="text-indent:-2em;margin-left:6em;">• Known TB exposure or ongoing risk factors for TB exposure (eg, travel to areas with high TB prevalence)</p></div>
</div>
</div>
<div class="block adr drugH1Div" id="F15897182"><span class="drugH1">Adverse Reactions</span>
<p style="text-indent:0em;display:inline">The following adverse drug reactions and incidences are derived from product labeling unless otherwise specified. Adverse reaction incidence reported in adults. Incidences of adverse reactions may include unapproved dosing regimens and combination therapy.</p>
<p style="text-indent:-2em;margin-left:2em;">&gt;10%:</p>
<p style="text-indent:-2em;margin-left:4em;">Endocrine &amp; metabolic: Hyperlipidemia (including increased HDL cholesterol [10% to 12%], increased LDL cholesterol [15% to 19%], increased serum cholesterol [total: ≤9%], and increased serum triglycerides [≤9%]).</p>
<p style="text-indent:-2em;margin-left:4em;">Infection: Infection (20% to 22%; including bacterial infection, BK virus, cryptococcosis, cytomegalovirus disease, fungal infection, histoplasmosis, listeriosis, mycobacterium infection, opportunistic infection, reactivation of HBV, serious infection, tuberculosis [including disseminated], viral infection [and reactivation])<span class="lexi-table-link-container"> (<a aria-label="Infection table link" class="lexi-table-link" data-table-id="lexi-content-infection" onclick="event.preventDefault(); window.mobileShowLexiTable &amp;&amp; mobileShowLexiTable('lexi-content-infection')">table 1</a>)</span><span class="table-link" style="display:none;">Infection</span></p>
<table border="1" class="lexi-modal-content" data-hyperlink="yes" data-table-id="Infection" frame="border" id="lexi-content-infection" rules="all">
<caption style="text-align:left;">
<b>Tofacitinib: Adverse Reaction: Infection</b></caption>
<colgroup><col align="left"/>
<col align="left"/>
<col align="left"/>
<col align="left"/>
<col align="left"/>
<col align="left"/>
</colgroup><thead>
<tr>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Drug (Tofacitinib)</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Placebo </b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Dose</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Indication</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Number of Patients (Tofacitinib)</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Number of Patients (Placebo)</b></p></th></tr></thead>
<tbody>
<tr>
<td align="left">
<p style="text-indent:0em;text-align:left;">22%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">18%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">10 mg twice daily</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Rheumatoid arthritis</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">1,349</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">809</p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;text-align:left;">20%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">18%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">5 mg twice daily</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Rheumatoid arthritis</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">1,336</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">809</p></td></tr></tbody></table>
<p style="text-indent:-2em;margin-left:4em;">Respiratory: Nasopharyngitis (3% to 14%)<span class="lexi-table-link-container"> (<a aria-label="Nasopharyngitis table link" class="lexi-table-link" data-table-id="lexi-content-nasopharyngitis" onclick="event.preventDefault(); window.mobileShowLexiTable &amp;&amp; mobileShowLexiTable('lexi-content-nasopharyngitis')">table 2</a>)</span><span class="table-link" style="display:none;">Nasopharyngitis</span></p>
<table border="1" class="lexi-modal-content" data-hyperlink="yes" data-table-id="Nasopharyngitis" frame="border" id="lexi-content-nasopharyngitis" rules="all">
<caption style="text-align:left;">
<b>Tofacitinib: Adverse Reaction: Nasopharyngitis</b></caption>
<colgroup><col align="left"/>
<col align="left"/>
<col align="left"/>
<col align="left"/>
<col align="left"/>
<col align="left"/>
</colgroup><thead>
<tr>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Drug (Tofacitinib)</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Placebo </b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Dose</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Indication</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Number of Patients (Tofacitinib)</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Number of Patients (Placebo)</b></p></th></tr></thead>
<tbody>
<tr>
<td align="left">
<p style="text-indent:0em;text-align:left;">4%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">3%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">5 mg twice daily</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Rheumatoid arthritis</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">1,336</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">809</p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;text-align:left;">3%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">3%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">10 mg twice daily</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Rheumatoid arthritis</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">1,349</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">809</p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;text-align:left;">14%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">6%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">10 mg twice daily</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Ulcerative colitis</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">196</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">198</p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;text-align:left;">10%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">6%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">5 mg twice daily</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Ulcerative colitis</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">198</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">198</p></td></tr></tbody></table>
<p style="text-indent:-2em;margin-left:2em;">1% to 10%:</p>
<p style="text-indent:-2em;margin-left:4em;">Cardiovascular: Hypertension (2%)</p>
<p style="text-indent:-2em;margin-left:4em;">Dermatologic: Acne vulgaris (≥2%), skin rash (6%)</p>
<p style="text-indent:-2em;margin-left:4em;">Gastrointestinal: Diarrhea (3% to 5%), gastroenteritis (4%), nausea (4%)</p>
<p style="text-indent:-2em;margin-left:4em;">Genitourinary: Urinary tract infection (2%)</p>
<p style="text-indent:-2em;margin-left:4em;">Hematologic &amp; oncologic: Anemia (2% to 4%)<span class="lexi-table-link-container"> (<a aria-label="Anemia table link" class="lexi-table-link" data-table-id="lexi-content-anemia" onclick="event.preventDefault(); window.mobileShowLexiTable &amp;&amp; mobileShowLexiTable('lexi-content-anemia')">table 3</a>)</span><span class="table-link" style="display:none;">Anemia</span></p>
<table border="1" class="lexi-modal-content" data-hyperlink="yes" data-table-id="Anemia" frame="border" id="lexi-content-anemia" rules="all">
<caption style="text-align:left;">
<b>Tofacitinib: Adverse Reaction: Anemia</b></caption>
<colgroup><col align="left"/>
<col align="left"/>
<col align="left"/>
<col align="left"/>
<col align="left"/>
<col align="left"/>
</colgroup><thead>
<tr>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Drug (Tofacitinib)</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Placebo </b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Dose</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Indication</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Number of Patients (Tofacitinib)</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Number of Patients (Placebo)</b></p></th></tr></thead>
<tbody>
<tr>
<td align="left">
<p style="text-indent:0em;text-align:left;">4%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">2%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">5 mg twice daily</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Ulcerative colitis</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">198</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">198</p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;text-align:left;">2%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">2%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">10 mg twice daily</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Ulcerative colitis</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">196</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">198</p></td></tr></tbody></table>
<p style="text-indent:-2em;margin-left:4em;">Infection: Herpes zoster infection (1% to 5%; including disseminated cutaneous, meningoencephalitis, ophthalmologic)<span class="lexi-table-link-container"> (<a aria-label="Herpes Zoster Infection table link" class="lexi-table-link" data-table-id="lexi-content-herpes-zoster-infection" onclick="event.preventDefault(); window.mobileShowLexiTable &amp;&amp; mobileShowLexiTable('lexi-content-herpes-zoster-infection')">table 4</a>)</span><span class="table-link" style="display:none;">Herpes Zoster Infection</span></p>
<table border="1" class="lexi-modal-content" data-hyperlink="yes" data-table-id="Herpes Zoster Infection" frame="border" id="lexi-content-herpes-zoster-infection" rules="all">
<caption style="text-align:left;">
<b>Tofacitinib: Adverse Reaction: Herpes Zoster Infection</b></caption>
<colgroup><col align="left"/>
<col align="left"/>
<col align="left"/>
<col align="left"/>
<col align="left"/>
<col align="left"/>
</colgroup><thead>
<tr>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Drug (Tofacitinib)</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Placebo </b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Dose</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Indication</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Number of Patients (Tofacitinib)</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Number of Patients (Placebo)</b></p></th></tr></thead>
<tbody>
<tr>
<td align="left">
<p style="text-indent:0em;text-align:left;">5%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">1%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">10 mg twice daily</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Ulcerative colitis</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">196</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">198</p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;text-align:left;">1%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">1%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">5 mg twice daily</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Ulcerative colitis</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">198</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">198</p></td></tr></tbody></table>
<p style="text-indent:-2em;margin-left:4em;">Nervous system: Headache (3% to 9%)</p>
<p style="text-indent:-2em;margin-left:4em;">Neuromuscular &amp; skeletal: Increased creatine phosphokinase in blood specimen (3% to 7%)</p>
<p style="text-indent:-2em;margin-left:4em;">Respiratory: Upper respiratory tract infection (4% to 7%)<span class="lexi-table-link-container"> (<a aria-label="Upper Respiratory Tract Infection table link" class="lexi-table-link" data-table-id="lexi-content-upper-respiratory-tract-infection" onclick="event.preventDefault(); window.mobileShowLexiTable &amp;&amp; mobileShowLexiTable('lexi-content-upper-respiratory-tract-infection')">table 5</a>)</span><span class="table-link" style="display:none;">Upper Respiratory Tract Infection</span></p>
<table border="1" class="lexi-modal-content" data-hyperlink="yes" data-table-id="Upper Respiratory Tract Infection" frame="border" id="lexi-content-upper-respiratory-tract-infection" rules="all">
<caption style="text-align:left;">
<b>Tofacitinib: Adverse Reaction: Upper Respiratory Tract Infection</b></caption>
<colgroup><col align="left"/>
<col align="left"/>
<col align="left"/>
<col align="left"/>
<col align="left"/>
<col align="left"/>
</colgroup><thead>
<tr>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Drug (Tofacitinib)</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Placebo </b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Dose</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Indication</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Number of Patients (Tofacitinib)</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Number of Patients (Placebo)</b></p></th></tr></thead>
<tbody>
<tr>
<td align="left">
<p style="text-indent:0em;text-align:left;">4%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">3%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">5 mg twice daily</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Rheumatoid arthritis</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">1,336</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">809</p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;text-align:left;">4%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">3%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">10 mg twice daily</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Rheumatoid arthritis</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">1,349</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">809</p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;text-align:left;">7%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">4%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">5 mg twice daily</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Ulcerative colitis</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">198</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">198</p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;text-align:left;">6%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">4%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">10 mg twice daily</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Ulcerative colitis</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">196</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">198</p></td></tr></tbody></table>
<p style="text-indent:-2em;margin-left:4em;">Miscellaneous: Fever (≥2%)</p>
<p style="text-indent:-2em;margin-left:2em;">&lt;1%: Hematologic &amp; oncologic: Lymphocytopenia (Wallenhaupt 2019), neutropenia (Wallenhaupt 2019)</p>
<p style="text-indent:-2em;margin-left:2em;">Frequency not defined:</p>
<p style="text-indent:-2em;margin-left:4em;">Cardiovascular: Peripheral edema</p>
<p style="text-indent:-2em;margin-left:4em;">Dermatologic: Cellulitis, erythema of skin, pruritus</p>
<p style="text-indent:-2em;margin-left:4em;">Endocrine &amp; metabolic: Dehydration</p>
<p style="text-indent:-2em;margin-left:4em;">Gastrointestinal: Abdominal pain, appendicitis, diverticulitis of the gastrointestinal tract, dyspepsia, esophageal candidiasis, gastritis, vomiting</p>
<p style="text-indent:-2em;margin-left:4em;">Hepatic: Liver steatosis</p>
<p style="text-indent:-2em;margin-left:4em;">Nervous system: Fatigue, insomnia, paresthesia</p>
<p style="text-indent:-2em;margin-left:4em;">Neuromuscular &amp; skeletal: Arthralgia, joint swelling, musculoskeletal pain, tendinopathy</p>
<p style="text-indent:-2em;margin-left:4em;">Renal: Increased serum creatinine</p>
<p style="text-indent:-2em;margin-left:4em;">Respiratory: Cough, dyspnea, infection due to an organism in genus <i>Pneumocystis</i>, interstitial lung disease, paranasal sinus congestion</p>
<p style="text-indent:-2em;margin-left:2em;">Postmarketing:</p>
<p style="text-indent:-2em;margin-left:4em;">Cardiovascular: Acute myocardial infarction (FDA 2021), arterial thrombosis (Mease 2020), deep vein thrombosis (Mease 2020), pulmonary embolism (Mease 2020), thrombosis (FDA 2019), venous thrombosis (Mease 2020)</p>
<p style="text-indent:-2em;margin-left:4em;">Dermatologic: Malignant melanoma, skin carcinoma (nonmelanoma) (Ytterberg 2022)</p>
<p style="text-indent:-2em;margin-left:4em;">Gastrointestinal: Gastrointestinal perforation (Xie 2016), malignant neoplasm of colon or rectum, pancreatic adenocarcinoma</p>
<p style="text-indent:-2em;margin-left:4em;">Genitourinary: Malignant neoplasm of breast, prostate carcinoma</p>
<p style="text-indent:-2em;margin-left:4em;">Hematologic &amp; oncologic: Gastric carcinoma, lymphocytosis (Wollenhaupt 2019), malignant lymphoma (Ytterberg 2022), malignant neoplasm (Ytterberg 2022), malignant solid tumor (Ytterberg 2022), thrombocytopenia (Kadoba 2020)</p>
<p style="text-indent:-2em;margin-left:4em;">Hepatic: Hepatotoxicity (Magri 2021), increased liver enzymes (Magri 2021)</p>
<p style="text-indent:-2em;margin-left:4em;">Hypersensitivity: Angioedema, hypersensitivity reaction</p>
<p style="text-indent:-2em;margin-left:4em;">Nervous system: Cerebrovascular accident (FDA 2021)</p>
<p style="text-indent:-2em;margin-left:4em;">Renal: Renal cell carcinoma</p>
<p style="text-indent:-2em;margin-left:4em;">Respiratory: Lung carcinoma, pneumonia (Wollenhaupt 2019)</p></div>
<div class="block coi drugH1Div" id="F15897117"><span class="drugH1">Contraindications</span>
<p style="text-indent:-2em;margin-left:2em;">There are no contraindications listed in the manufacturer's US labeling.</p>
<p style="text-indent:-2em;margin-left:2em;">
<i>Canadian labeling:</i> Hypersensitivity to tofacitinib or any component of the formulation; severe hepatic impairment; pregnancy; breastfeeding.</p></div>
<div class="block war drugH1Div" id="F15897118"><span class="drugH1">Warnings/Precautions</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Concerns related to adverse effects: </i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Hypersensitivity: Hypersensitivity reactions, including angioedema and urticaria, have occurred; discontinue therapy and evaluate cause for serious reactions.</p>
<p style="text-indent:-2em;margin-left:4em;">• Interstitial lung disease: Interstitial lung disease (ILD) has been reported; patients developing ILD were receiving concomitant therapy associated with ILD (eg, methotrexate). Use with caution in patients with risk/history of ILD (Xeljanz Canadian product monograph).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Disease-related concerns: </i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Active infections: Do not initiate tofacitinib in patients with active infections, including localized infections.</p>
<p style="text-indent:-2em;margin-left:4em;">• Hepatic impairment: Use with caution in patients with hepatic impairment; see "Dosing: Hepatic Impairment" for additional information.</p>
<p style="text-indent:-2em;margin-left:4em;">• Lung disease: Patients with a history of chronic lung disease or those who develop interstitial lung disease may be more prone to infections; use with caution.</p>
<p style="text-indent:-2em;margin-left:4em;">• Renal impairment: Use with caution in patients with renal impairment; see "Dosing: Altered Kidney Function" for additional information.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Concurrent drug therapy issues:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Immunosuppressant medications: Tofacitinib should not be administered in combination with strong immunosuppressive medications (eg, azathioprine, tacrolimus, cyclosporine) due to the risk of additive immunosuppression; such combinations have not been studied in RA.</p>
<p style="text-indent:-2em;margin-left:4em;">• Biologic disease-modifying antirheumatic drugs: Tofacitinib should not be administered in combination with biologic disease-modifying antirheumatic drugs.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Special populations:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Asian patients: Use with caution in Asian patients; an increased incidence of adverse reactions (eg, herpes zoster, opportunistic infections, decreased WBC, interstitial lung disease, increased transaminases) has been observed (Wollenhaupt 2014; Xeljanz Canadian product monograph).</p>
<p style="text-indent:-2em;margin-left:4em;">• Patients with rheumatic musculoskeletal disease undergoing hip or knee replacement surgery: Hold tofacitinib for at least 3 days prior to surgery to reduce infection risk; therapy can be restarted once surgical wound shows evidence of healing (eg, no swelling, erythema, or drainage), sutures/staples are removed, and no ongoing nonsurgical site infections (typically ~14 days to reduce infection risk) (ACR/AAHKS [Goodman 2022]).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Dosage form specific issues: </i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Benzyl alcohol and derivatives: Some dosage forms may contain benzyl alcohol and/or sodium benzoate/benzoic acid; benzoic acid (benzoate) is a metabolite of benzyl alcohol. Large amounts of benzyl alcohol (≥99 mg/kg/day) have been associated with a potentially fatal toxicity ("gasping syndrome") in neonates. The "gasping syndrome" consists of metabolic acidosis, respiratory distress, gasping respirations, CNS dysfunction (including convulsions, intracranial hemorrhage), hypotension, and cardiovascular collapse (AAP ["Inactive" 1997]; CDC 1982). Some data suggest that benzoate displaces bilirubin from protein-binding sites (Ahlfors 2001); avoid or use dosage forms containing benzyl alcohol and/or benzyl alcohol derivative with caution in neonates. See manufacturer's labeling.</p>
<p style="text-indent:-2em;margin-left:4em;">• Extended release: Use caution when administering the ER formulation to patients with preexisting severe GI narrowing (pathologic or iatrogenic). There have been rare reports of obstructive symptoms in patients with known strictures following ingestion of other medications that also utilize a nondeformable ER formulation. The inert tablet shell of the ER tablet may be noticeable in the stool (or colostomy); the active medication will have been already absorbed.</p>
<p style="text-indent:-2em;margin-left:4em;">• Non-interchangeability of dosage forms: ER tablets are not interchangeable or substitutable with the oral solution.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Other warnings/precautions:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Immunizations: Immunization status should be current before initiating therapy. Live vaccines should not be given concomitantly with tofacitinib; recommended interval between receipt of live vaccines and initiation of immunosuppressive agents, such as tofacitinib, should follow current vaccination clinical guidelines. Dissemination of the vaccine strain of varicella zoster virus has been reported in a varicella virus-naive patient 16 days following vaccination with Zostavax (live attenuated zoster) and 2 days after the initiation of tofacitinib.</p></div>
<div class="block foc drugH1Div" id="F54979821"><span class="drugH1">Dosage Forms: US</span>
<p style="text-indent:0em;text-align:justify;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Solution, Oral, as citrate [strength expressed as base]: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Xeljanz: 1 mg/mL (240 mL) [contains sodium benzoate]</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Tablet, Oral, as citrate [strength expressed as base]: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Xeljanz: 5 mg</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Xeljanz: 10 mg [contains fd&amp;c blue #1 (brill blue) aluminum lake, fd&amp;c blue #2 (indigotine,indigo carmine)]</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Tablet Extended Release 24 Hour, Oral, as citrate [strength expressed as base]: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Xeljanz XR: 11 mg</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Xeljanz XR: 22 mg [contains fd&amp;c blue #2 (indigo carm) aluminum lake]</p></div>
<div class="block geq drugH1Div" id="F20452829"><span class="drugH1">Generic Equivalent Available: US</span>
<p style="text-indent:0em;display:inline">No</p></div>
<div class="block fee drugH1Div" id="F16570460"><span class="drugH1">Pricing: US</span>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Solution</b> (Xeljanz Oral)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">1 mg/mL (per mL): $23.14</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Tablet, 24-hour</b> (Xeljanz XR Oral)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">11 mg (per each): $231.36</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">22 mg (per each): $231.36</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Tablets</b> (Xeljanz Oral)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">5 mg (per each): $115.68</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">10 mg (per each): $115.68</p>
<p style="text-indent:0em;">
<b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>
<div class="block dinfoc drugH1Div" id="F52871529"><span class="drugH1">Dosage Forms: Canada</span>
<p style="text-indent:0em;text-align:justify;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Tablet, Oral, as citrate [strength expressed as base]: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Xeljanz: 5 mg</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Xeljanz: 10 mg [contains fd&amp;c blue #1 (brill blue) aluminum lake, fd&amp;c blue #2 (indigo carm) aluminum lake]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 5 mg, 10 mg</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Tablet Extended Release 24 Hour, Oral, as citrate [strength expressed as base]: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Xeljanz XR: 11 mg</p></div>
<div class="block accres drugH1Div" id="F15897112"><span class="drugH1">Prescribing and Access Restrictions</span>
<p style="text-indent:0em;display:inline">Available through specialty/network pharmacies. Further information may be obtained from the manufacturer, Pfizer Inc, at 1-855-493-5526 or at http://www.xeljanz.com/.</p></div>
<div class="block admp drugH1Div" id="F54975491"><span class="drugH1">Administration: Pediatric</span>
<p style="text-indent:-2em;margin-left:2em;">Oral: Oral solution, immediate-release tablets: May be taken with or without food.</p>
<p style="text-indent:-2em;margin-left:4em;">Oral solution: Use provided bottle adapter to attach oral syringe. After each use store bottle in carton to protect from light, rinse oral syringe with water, and allow to air dry. Discard any remaining oral solution 60 days after opening bottle.</p></div>
<div class="block adm drugH1Div" id="F15897305"><span class="drugH1">Administration: Adult</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>Oral:</b> May be taken with or without food.</p>
<p style="text-indent:-2em;margin-left:2em;">Extended release: Swallow tablet whole and intact; do not crush, split, or chew.</p>
<p style="text-indent:-2em;margin-left:4em;">Bariatric surgery: Some institutions may have specific protocols that conflict with these recommendations; refer to institutional protocols as appropriate. IR tablet formulation is available. If safety and efficacy can be effectively monitored, no change in formulation or administration is required after bariatric surgery.</p></div>
<div class="block hazard drugH1Div" id="F49104591"><span class="drugH1">Hazardous Drugs Handling Considerations</span>
<p style="text-indent:0em;">Hazardous agent (NIOSH 2016 [group 2]).</p>
<p style="text-indent:0em;margin-top:2em;">Use appropriate precautions for receiving, handling, administration, and disposal. Gloves (single) should be worn during receiving, unpacking, and placing in storage. NIOSH recommends single gloving for administration of intact tablets or capsules (NIOSH 2016). Assess risk to determine appropriate containment strategy (USP-NF 2017).</p></div>
<div class="block sts drugH1Div" id="F15897247"><span class="drugH1">Storage/Stability</span>
<p style="text-indent:-2em;margin-left:2em;">Oral solution: Store in original container at 20°C to 25°C (68°F to 77°F); excursions permitted between 15°C and 30°C (59°F and 86°F). Protect from light. Discard any unused amount 60 days after opening.</p>
<p style="text-indent:-2em;margin-left:2em;">Tablets: Store at 20°C to 25°C (68°F to 77°F).</p></div>
<div class="block meg drugH1Div" id="F15784558"><span class="drugH1">Medication Guide and/or Vaccine Information Statement (VIS)</span>
<p style="text-indent:0em;display:inline">An FDA-approved patient medication guide, which is available with the product information and as follows, must be dispensed with this medication:</p>
<p style="text-indent:-2em;margin-left:4em;">Xeljanz, Xeljanz XR: <a href="/external-redirect?target_url=https%3A%2F%2Fwww.accessdata.fda.gov%2Fdrugsatfda_docs%2Flabel%2F2021%2F203214s028%2C208246s013%2C213082s003lbl.pdf%23page%3D66&amp;token=QYQ2CPn8qRPeBGvJEqsXnlrnF5USZn%2BS8d4RXakwj5PIFypmLJ1P4aGrXiupSKv7D2MPxsnVknUDHORUpJEuFJIItc8%2BIxrmKdb3ijdL1qW8Nl%2FYDnIu7F7kBn1LKI5AT%2BK3zKLOchWmJnwLj%2F0llw%3D%3D&amp;TOPIC_ID=129936" target="_blank">https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/203214s028,208246s013,213082s003lbl.pdf#page=66</a></p></div>
<div class="block usep drugH1Div" id="F54975487"><span class="drugH1">Use</span>
<p style="text-indent:0em;display:inline">Treatment of active polyarticular course juvenile idiopathic arthritis (Oral solution, immediate-release [IR] tablet: FDA approved in pediatric patients ≥2 years); treatment of active psoriatic arthritis in patients who have had an inadequate response or are intolerant to methotrexate or other disease-modifying antirheumatic drugs (DMARDs) (Tablets [IR/extended-release (ER)]: FDA approved in adults); treatment of moderately to severely active rheumatoid arthritis in patients who have had an inadequate response to or are intolerant to methotrexate (Tablets [IR/ER]: FDA approved in adults); treatment of moderately to severely acute ulcerative colitis in patients who have had an inadequate response to or are intolerant to tumor necrosis factor blockers (Tablets [IR/ER]: FDA approved in adults).</p></div>
<div class="block mst drugH1Div" id="F56413183"><span class="drugH1">Medication Safety Issues</span>
<div class="collapsible">
<span class="collapsible-title">High alert medication:</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:4em;">The Institute for Safe Medication Practices (ISMP) includes this medication among its list of drugs that have a heightened risk of causing significant patient harm when used in error.</p></div>
</div>
</div>
<div class="block cyt drugH1Div" id="F15977374"><span class="drugH1">Metabolism/Transport Effects</span>
<p style="text-indent:0em;display:inline">
<b>Substrate</b> of CYP2C19 (minor), CYP3A4 (major); <b>Note:</b> Assignment of Major/Minor substrate status based on clinically relevant drug interaction potential</p></div>
<div class="block dri drugH1Div" id="F15977370"><span class="drugH1">Drug Interactions</span><br/><br/><div class="clear"></div><p xmlns=""></p><div class="inner" xmlns=""><p style="text-indent:0em;display:inline"><b>Note</b>: Interacting drugs may <b>not be individually listed below</b> if they are part of a group interaction (eg, individual drugs within “CYP3A4 Inducers [Strong]” are NOT listed).  For a complete list of drug interactions by individual drug name and detailed management recommendations, use the Lexicomp drug interactions program by clicking on the “Launch drug interactions program” link above.</p><p xmlns=""></p></div>
<p style="text-indent:-2em;margin-left:2em;">5-Aminosalicylic Acid Derivatives: May enhance the myelosuppressive effect of Myelosuppressive Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Abrocitinib: May enhance the immunosuppressive effect of Immunosuppressants (Therapeutic Immunosuppressant Agents).<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Anifrolumab: Biologic Disease-Modifying Antirheumatic Drugs (DMARDs) may enhance the immunosuppressive effect of Anifrolumab. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Baricitinib: Immunosuppressants (Therapeutic Immunosuppressant Agents) may enhance the immunosuppressive effect of Baricitinib. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">BCG (Intravesical): Myelosuppressive Agents may diminish the therapeutic effect of BCG (Intravesical). <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">BCG Products: Immunosuppressants (Therapeutic Immunosuppressant Agents) may enhance the adverse/toxic effect of BCG Products. Specifically, the risk of vaccine-associated infection may be increased. Immunosuppressants (Therapeutic Immunosuppressant Agents) may diminish the therapeutic effect of BCG Products. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Bradycardia-Causing Agents: Tofacitinib may enhance the bradycardic effect of Bradycardia-Causing Agents. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Brincidofovir: Immunosuppressants (Therapeutic Immunosuppressant Agents) may diminish the therapeutic effect of Brincidofovir. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Brivudine: May enhance the adverse/toxic effect of Immunosuppressants (Therapeutic Immunosuppressant Agents).<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Chikungunya Vaccine (Live): Immunosuppressants (Therapeutic Immunosuppressant Agents) may enhance the adverse/toxic effect of Chikungunya Vaccine (Live). Specifically, the risk of vaccine-associated infection may be increased. Immunosuppressants (Therapeutic Immunosuppressant Agents) may diminish the therapeutic effect of Chikungunya Vaccine (Live). <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Chloramphenicol (Ophthalmic): May enhance the adverse/toxic effect of Myelosuppressive Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Chloramphenicol (Systemic): Myelosuppressive Agents may enhance the myelosuppressive effect of Chloramphenicol (Systemic). <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Cladribine: May enhance the myelosuppressive effect of Myelosuppressive Agents.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Cladribine: Immunosuppressants (Therapeutic Immunosuppressant Agents) may enhance the immunosuppressive effect of Cladribine. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Clofazimine: May increase the serum concentration of CYP3A4 Substrates (High risk with Inhibitors).<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">CloZAPine: Myelosuppressive Agents may enhance the adverse/toxic effect of CloZAPine. Specifically, the risk for neutropenia may be increased. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Coccidioides immitis Skin Test: Immunosuppressants (Therapeutic Immunosuppressant Agents) may diminish the diagnostic effect of Coccidioides immitis Skin Test.  Management: Consider discontinuing therapeutic immunosuppressants several weeks prior to coccidioides immitis skin antigen testing to increase the likelihood of accurate diagnostic results.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Corticosteroids (Systemic): May enhance the immunosuppressive effect of Tofacitinib. Management: Coadministration of tofacitinib with potent immunosuppressants is not recommended. Doses equivalent to more than 2 mg/kg or 20 mg/day of prednisone (for persons over 10 kg) administered for 2 or more weeks are considered immunosuppressive.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">COVID-19 Vaccines: Tofacitinib may diminish the therapeutic effect of COVID-19 Vaccines.  Management: Rheumatology guidelines recommend holding baricitinib, tofactinib, or upadacitinib for 1 to 2 weeks after vaccine administration as permitted by the underlying disease.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">CYP3A4 Inducers (Moderate): May decrease the serum concentration of Tofacitinib.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">CYP3A4 Inducers (Strong): May decrease the serum concentration of Tofacitinib.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">CYP3A4 Inhibitors (Moderate): May increase the serum concentration of Tofacitinib.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">CYP3A4 Inhibitors (Strong): May increase the serum concentration of Tofacitinib. Management: Tofacitinib dose reductions are recommended when combined with strong CYP3A4 inhibitors. Recommended dose adjustments vary by tofacitinib formulation and therapeutic indication. See full Lexi Interact monograph for details.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Deferiprone: Myelosuppressive Agents may enhance the neutropenic effect of Deferiprone.  Management: Avoid the concomitant use of deferiprone and myelosuppressive agents whenever possible. If this combination cannot be avoided, monitor the absolute neutrophil count more closely.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Dengue Tetravalent Vaccine (Live): Immunosuppressants (Therapeutic Immunosuppressant Agents) may enhance the adverse/toxic effect of Dengue Tetravalent Vaccine (Live). Specifically, the risk of vaccine-associated infection may be increased. Immunosuppressants (Therapeutic Immunosuppressant Agents) may diminish the therapeutic effect of Dengue Tetravalent Vaccine (Live). <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Denosumab: Immunosuppressants (Therapeutic Immunosuppressant Agents) may enhance the immunosuppressive effect of Denosumab.  Management: Consider the risk of serious infections versus the potential benefits of coadministration of denosumab and immunosuppressants. If combined, monitor for signs/symptoms of serious infections.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Deucravacitinib: May enhance the immunosuppressive effect of Immunosuppressants (Therapeutic Immunosuppressant Agents).<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Dipyrone: May enhance the adverse/toxic effect of Myelosuppressive Agents. Specifically, the risk for agranulocytosis and pancytopenia may be increased<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Etrasimod: May enhance the immunosuppressive effect of Immunosuppressants (Therapeutic Immunosuppressant Agents).<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Fexinidazole: May increase the serum concentration of CYP3A4 Substrates (High risk with Inhibitors).<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Fexinidazole: Myelosuppressive Agents may enhance the myelosuppressive effect of Fexinidazole. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Filgotinib: May enhance the immunosuppressive effect of Immunosuppressants (Therapeutic Immunosuppressant Agents).<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Fluconazole: May increase the serum concentration of Tofacitinib. Management: Tofacitinib dose reductions are recommended when combined with fluconazole. Recommended dose adjustments vary by tofacitinib formulation and therapeutic indication. See full Lexi Interact monograph for details.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Fusidic Acid (Systemic): May increase the serum concentration of CYP3A4 Substrates (High risk with Inhibitors).<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Immunosuppressants (Cytotoxic Chemotherapy): May enhance the immunosuppressive effect of Tofacitinib.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Immunosuppressants (Miscellaneous Oncologic Agents): May enhance the immunosuppressive effect of Tofacitinib.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Immunosuppressants (Therapeutic Immunosuppressant Agents): May enhance the immunosuppressive effect of Tofacitinib. Management: Coadministration of tofacitinib with potent immunosuppressants is not recommended. Use with non-biologic disease-modifying antirheumatic drugs (DMARDs) was permitted in psoriatic arthritis clinical trials.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Influenza Virus Vaccines: Immunosuppressants (Therapeutic Immunosuppressant Agents) may diminish the therapeutic effect of Influenza Virus Vaccines.  Management: Administer influenza vaccines at least 2 weeks prior to initiating immunosuppressants if possible. If vaccination occurs less than 2 weeks prior to or during therapy, revaccinate 2 to 3 months after therapy discontinued if immune competence restored.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Methotrexate: May enhance the immunosuppressive effect of Tofacitinib. Management: Concomitant use of tofacitinib with high-dose or IV methotrexate is not recommended. Use with antirheumatic doses of methotrexate is permitted, and if combined, patients should be monitored for infection.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Mumps- Rubella- or Varicella-Containing Live Vaccines: Immunosuppressants (Therapeutic Immunosuppressant Agents) may enhance the adverse/toxic effect of Mumps- Rubella- or Varicella-Containing Live Vaccines. Specifically, the risk of vaccine-associated infection may be increased. Immunosuppressants (Therapeutic Immunosuppressant Agents) may diminish the therapeutic effect of Mumps- Rubella- or Varicella-Containing Live Vaccines. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Nadofaragene Firadenovec: Immunosuppressants (Therapeutic Immunosuppressant Agents) may enhance the adverse/toxic effect of Nadofaragene Firadenovec. Specifically, the risk of disseminated adenovirus infection may be increased. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Natalizumab: Immunosuppressants (Therapeutic Immunosuppressant Agents) may enhance the immunosuppressive effect of Natalizumab. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Olaparib: Myelosuppressive Agents may enhance the myelosuppressive effect of Olaparib. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Pidotimod: Immunosuppressants (Therapeutic Immunosuppressant Agents) may diminish the therapeutic effect of Pidotimod. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Pimecrolimus: Immunosuppressants (Therapeutic Immunosuppressant Agents) may enhance the immunosuppressive effect of Pimecrolimus. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Pneumococcal Vaccines: Immunosuppressants (Therapeutic Immunosuppressant Agents) may diminish the therapeutic effect of Pneumococcal Vaccines. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Poliovirus Vaccine (Live/Trivalent/Oral): Immunosuppressants (Therapeutic Immunosuppressant Agents) may enhance the adverse/toxic effect of Poliovirus Vaccine (Live/Trivalent/Oral). Specifically, the risk of vaccine-associated infection may be increased. Immunosuppressants (Therapeutic Immunosuppressant Agents) may diminish the therapeutic effect of Poliovirus Vaccine (Live/Trivalent/Oral). <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Polymethylmethacrylate: Immunosuppressants (Therapeutic Immunosuppressant Agents) may enhance the potential for allergic or hypersensitivity reactions to Polymethylmethacrylate.  Management: Use caution when considering use of bovine collagen-containing implants such as the polymethylmethacrylate-based Bellafill brand implant in patients who are receiving immunosuppressants. Consider use of additional skin tests prior to administration.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Promazine: May enhance the myelosuppressive effect of Myelosuppressive Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Rabies Vaccine: Immunosuppressants (Therapeutic Immunosuppressant Agents) may diminish the therapeutic effect of Rabies Vaccine.  Management: Complete rabies vaccination at least 2 weeks before initiation of immunosuppressant therapy if possible. If combined, check for rabies antibody titers, and if vaccination is for post exposure prophylaxis, administer a 5th dose of the vaccine.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ritlecitinib: Immunosuppressants (Therapeutic Immunosuppressant Agents) may enhance the immunosuppressive effect of Ritlecitinib. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ropeginterferon Alfa-2b: Myelosuppressive Agents may enhance the myelosuppressive effect of Ropeginterferon Alfa-2b.  Management: Avoid coadministration of ropeginterferon alfa-2b and other myelosuppressive agents. If this combination cannot be avoided, monitor patients for excessive myelosuppressive effects.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ruxolitinib (Topical): Immunosuppressants (Therapeutic Immunosuppressant Agents) may enhance the immunosuppressive effect of Ruxolitinib (Topical). <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Sipuleucel-T: Immunosuppressants (Therapeutic Immunosuppressant Agents) may diminish the therapeutic effect of Sipuleucel-T.  Management: Consider reducing the dose or discontinuing the use of immunosuppressants prior to initiating sipuleucel-T therapy.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Tacrolimus (Topical): Immunosuppressants (Therapeutic Immunosuppressant Agents) may enhance the immunosuppressive effect of Tacrolimus (Topical). <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Talimogene Laherparepvec: Immunosuppressants (Therapeutic Immunosuppressant Agents) may enhance the adverse/toxic effect of Talimogene Laherparepvec. Specifically, the risk of infection from the live, attenuated herpes simplex virus contained in talimogene laherparepvec may be increased. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Tertomotide: Immunosuppressants (Therapeutic Immunosuppressant Agents) may diminish the therapeutic effect of Tertomotide. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Typhoid Vaccine: Immunosuppressants (Therapeutic Immunosuppressant Agents) may enhance the adverse/toxic effect of Typhoid Vaccine. Specifically, the risk of vaccine-associated infection may be increased. Immunosuppressants (Therapeutic Immunosuppressant Agents) may diminish the therapeutic effect of Typhoid Vaccine. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Upadacitinib: Immunosuppressants (Therapeutic Immunosuppressant Agents) may enhance the immunosuppressive effect of Upadacitinib. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Vaccines (Inactivated/Non-Replicating): Immunosuppressants (Therapeutic Immunosuppressant Agents) may diminish the therapeutic effect of Vaccines (Inactivated/Non-Replicating).  Management: Give inactivated vaccines at least 2 weeks prior to initiation of immunosuppressants when possible. Patients vaccinated less than 14 days before initiating or during therapy should be revaccinated at least 2 to 3 months after therapy is complete.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Vaccines (Live): Immunosuppressants (Therapeutic Immunosuppressant Agents) may enhance the adverse/toxic effect of Vaccines (Live). Specifically, the risk of vaccine-associated infection may be increased. Immunosuppressants (Therapeutic Immunosuppressant Agents) may diminish the therapeutic effect of Vaccines (Live). <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Yellow Fever Vaccine: Immunosuppressants (Therapeutic Immunosuppressant Agents) may enhance the adverse/toxic effect of Yellow Fever Vaccine. Specifically, the risk of vaccine-associated infection may be increased. Immunosuppressants (Therapeutic Immunosuppressant Agents) may diminish the therapeutic effect of Yellow Fever Vaccine. <i> Risk X: Avoid combination</i></p></div>
<div class="block rep_considerations drugH1Div" id="F55608355"><span class="drugH1">Reproductive Considerations</span>
<p style="text-indent:0em;">Recommendations for use of tofacitinib to treat rheumatic and musculoskeletal diseases in patients planning to become pregnant or who are planning to father a child are not available due to lack of data (ACR [Sammaritano 2020]).</p>
<p style="text-indent:0em;margin-top:2em;">Agents other than tofacitinib are preferred to treat inflammatory bowel disease in patients planning to become pregnant. Disease management should be optimized prior to pregnancy. Tofacitinib should be avoided or used with caution prior to a planned pregnancy; discontinue 1 week prior to conception to limit first trimester fetal exposure (Mahadevan 2019).</p></div>
<div class="block pri drugH1Div" id="F15897114"><span class="drugH1">Pregnancy Considerations</span>
<p style="text-indent:0em;">Outcome data following tofacitinib exposure during pregnancy are limited (Clowse 2016; Fernández-Sánchez 2021; Mahadevan 2018).</p>
<p style="text-indent:0em;margin-top:2em;">Recommendations for use of tofacitinib in pregnant patients with rheumatic and musculoskeletal diseases are not available due to lack of data. Placental transfer may be expected based on molecular weight (ACR [Sammaritano 2020]).</p>
<p style="text-indent:0em;margin-top:2em;">Inflammatory bowel disease is associated with adverse pregnancy outcomes, including an increased risk of miscarriage, premature delivery, delivery of a low-birth-weight infant, and poor maternal weight gain. Management of maternal disease should be optimized prior to pregnancy. Treatment decreases disease flares, disease activity, and the incidence of adverse pregnancy outcomes. When treatment for inflammatory bowel disease is needed in pregnant patients, use of tofacitinib should be avoided at least during the first trimester (Mahadevan 2019).</p>
<p style="text-indent:0em;margin-top:2em;">Tofacitinib is under study for the treatment of COVID-19 (NIH 2023). The risk of severe morbidity and mortality from COVID-19 infection is increased in pregnant patients compared to nonpregnant patients. Pregnant and recently pregnant patients with moderate or severe infection are at increased risk of complications such as hypertensive disorders of pregnancy, postpartum hemorrhage, or other infections compared to pregnant patients without COVID-19. Pregnant patients with symptoms may require ICU admission, mechanical ventilation, or ventilatory support (extracorporeal membrane oxygenation). Other adverse pregnancy outcomes include preterm birth and stillbirth. The risk of coagulopathy, cesarean delivery, and maternal death may be increased; neonates have an increased risk for NICU admission. Maternal age and comorbidities such as diabetes, hypertension, lung disease, and obesity may also increase the risk of severe illness in pregnant and recently pregnant patients (ACOG 2023; NIH 2023).</p>
<p style="text-indent:0em;margin-top:2em;">In general, the treatment of COVID-19 infection during pregnancy is the same as in nonpregnant patients. However, because data for most therapeutic agents in pregnant patients are limited, treatment options should be evaluated as part of a shared decision-making process. Use of an agent other than tofacitinib may be preferred (NIH 2023). Information related to the treatment of COVID-19 during pregnancy continues to emerge; refer to current guidelines for the treatment of pregnant patients.</p></div>
<div class="block mopp drugH1Div" id="F54975492"><span class="drugH1">Monitoring Parameters</span>
<p style="text-indent:0em;display:inline">Lymphocyte count (baseline and every 3 months thereafter); neutrophil/platelet counts (baseline, after 4 to 8 weeks, and every 3 months thereafter); hemoglobin (baseline, after 4 to 8 weeks, and every 3 months thereafter); lipids (4 to 8 weeks after therapy initiation and periodically); LFTs; signs and symptoms of infections (including tuberculosis) during and after therapy; abdominal symptoms; skin examinations (periodically, in patients at increased risk for skin cancer); heart rate and blood pressure at baseline and periodically thereafter.</p></div>
<div class="block pha drugH1Div" id="F15897248"><span class="drugH1">Mechanism of Action</span>
<p style="text-indent:0em;display:inline">Tofacitinib inhibits Janus kinase (JAK) enzymes, which are intracellular enzymes involved in stimulating hematopoiesis and immune cell function through a signaling pathway. In response to extracellular cytokine or growth factor signaling, JAKs activate signal transducers and activators of transcription (STATs), which regulate gene expression and intracellular activity. Inhibition of JAKs prevents cytokine- or growth factor-mediated gene expression and intracellular activity of immune cells, reduces circulating CD16/56+ natural killer cells, serum IgG, IgM, IgA, and C-reactive protein, and increases B cells.</p></div>
<div class="block phk drugH1Div" id="F15897250"><span class="drugH1">Pharmacokinetics (Adult Data Unless Noted)</span>
<p style="text-indent:-2em;margin-left:2em;">Absorption: Oral:</p>
<p style="text-indent:-2em;margin-left:4em;">IR tablet: Rapid (74%); C<sub>max</sub> is reduced by 32% when administered with high-fat meal, but AUC remains unchanged.</p>
<p style="text-indent:-2em;margin-left:4em;">Extended release: When administered with high-fat meal, C<sub>max</sub>,following an 11 mg and 22 mg dose, increased by 27% and 19%, respectively, and T<sub>max</sub> was extended by ~1 hour, but AUC remains unchanged.</p>
<p style="text-indent:-2em;margin-left:2em;">Distribution: V<sub>d</sub>: 87 L.</p>
<p style="text-indent:-2em;margin-left:2em;">Bioavailability: The AUC and C<sub>max</sub> of 11 mg extended release once daily are equivalent to 5 mg IR tablet administered twice daily.</p>
<p style="text-indent:-2em;margin-left:2em;">Protein binding: ~40% (predominantly to albumin).</p>
<p style="text-indent:-2em;margin-left:2em;">Metabolism: Hepatic (70%): CYP3A4 and CYP2C19 to inactive metabolites.</p>
<p style="text-indent:-2em;margin-left:2em;">Half-life elimination: ~3 hours (IR solution, tablet); ~6 to 8 hours (extended release).</p>
<p style="text-indent:-2em;margin-left:2em;">Time to peak: 0.5 to 1 hour (IR solution, tablet); 4 hours (extended release).</p>
<p style="text-indent:-2em;margin-left:2em;">Excretion: Primarily urine (30%) as unchanged drug.</p></div>
<div class="block phksp drugH1Div" id="F51204297"><span class="drugH1">Pharmacokinetics: Additional Considerations (Adult Data Unless Noted)</span>
<p style="text-indent:-2em;margin-left:2em;">Altered kidney function: AUC increased ~1.75- to 2.5-fold in moderate and severe renal impairment.</p>
<p style="text-indent:-2em;margin-left:2em;">Hepatic function impairment: AUC and C<sub>max</sub> increased ~1.5-fold in moderate hepatic impairment.</p></div>
<div class="list fbnlist drugH1Div drugBrandNames" id="F22059516"><span class="drugH1">Brand Names: International</span><div class="ibn-search drugBrandNames"></div>
<div class="collapsible-indication brand-names-accordion drugBrandNames"><span class="collapsible-indication-title">International Brand Names by Country</span><div class="collapsible-indication-wrap-frame drugBrandNames"><div class="collapsible-indication-wrap drugBrandNames">For country code abbreviations (<a class="graphic graphic_table" href="/d/html/116421.html" rel="external">show table</a>)<br xmlns=""/><br/><ul>
<li>
<span class="countryCode">(AE)</span> <span class="country">United Arab Emirates</span><span class="countrySeparator">: </span><span class="drugName">Xeljanz</span>;</li>
<li>
<span class="countryCode">(AR)</span> <span class="country">Argentina</span><span class="countrySeparator">: </span><span class="drugName">Atexa | Intrart | Janvax | Klaxon | Rofek | Rofek xr | Terfanib | Tofax | Tolvar | Xeljanz | Xeljanz XR</span>;</li>
<li>
<span class="countryCode">(AT)</span> <span class="country">Austria</span><span class="countrySeparator">: </span><span class="drugName">Xeljanz</span>;</li>
<li>
<span class="countryCode">(AU)</span> <span class="country">Australia</span><span class="countrySeparator">: </span><span class="drugName">Xeljanz</span>;</li>
<li>
<span class="countryCode">(BD)</span> <span class="country">Bangladesh</span><span class="countrySeparator">: </span><span class="drugName">Arthanib | Arthanib xr | Jakloc | Jaktor | Tocit | Tofacent | Tofacit | Tofacit xr | Tofanib | Tofatin | Tofator | Tojak</span>;</li>
<li>
<span class="countryCode">(BE)</span> <span class="country">Belgium</span><span class="countrySeparator">: </span><span class="drugName">Xeljanz</span>;</li>
<li>
<span class="countryCode">(BG)</span> <span class="country">Bulgaria</span><span class="countrySeparator">: </span><span class="drugName">Xeljanz | Xeljanz XR</span>;</li>
<li>
<span class="countryCode">(BR)</span> <span class="country">Brazil</span><span class="countrySeparator">: </span><span class="drugName">Xeljanz</span>;</li>
<li>
<span class="countryCode">(CH)</span> <span class="country">Switzerland</span><span class="countrySeparator">: </span><span class="drugName">Xeljanz</span>;</li>
<li>
<span class="countryCode">(CL)</span> <span class="country">Chile</span><span class="countrySeparator">: </span><span class="drugName">Xeljanz | Xeljanz XR</span>;</li>
<li>
<span class="countryCode">(CO)</span> <span class="country">Colombia</span><span class="countrySeparator">: </span><span class="drugName">Xeljanz | Xeljanz XR</span>;</li>
<li>
<span class="countryCode">(CZ)</span> <span class="country">Czech Republic</span><span class="countrySeparator">: </span><span class="drugName">Xeljanz</span>;</li>
<li>
<span class="countryCode">(DE)</span> <span class="country">Germany</span><span class="countrySeparator">: </span><span class="drugName">Xeljanz</span>;</li>
<li>
<span class="countryCode">(EC)</span> <span class="country">Ecuador</span><span class="countrySeparator">: </span><span class="drugName">Xeljanz</span>;</li>
<li>
<span class="countryCode">(EE)</span> <span class="country">Estonia</span><span class="countrySeparator">: </span><span class="drugName">Xeljanz</span>;</li>
<li>
<span class="countryCode">(EG)</span> <span class="country">Egypt</span><span class="countrySeparator">: </span><span class="drugName">Xeljanz | Xeljanz XR</span>;</li>
<li>
<span class="countryCode">(ES)</span> <span class="country">Spain</span><span class="countrySeparator">: </span><span class="drugName">Xeljanz</span>;</li>
<li>
<span class="countryCode">(FI)</span> <span class="country">Finland</span><span class="countrySeparator">: </span><span class="drugName">Xeljanz</span>;</li>
<li>
<span class="countryCode">(FR)</span> <span class="country">France</span><span class="countrySeparator">: </span><span class="drugName">Xeljanz</span>;</li>
<li>
<span class="countryCode">(GB)</span> <span class="country">United Kingdom</span><span class="countrySeparator">: </span><span class="drugName">Xeljanz</span>;</li>
<li>
<span class="countryCode">(GR)</span> <span class="country">Greece</span><span class="countrySeparator">: </span><span class="drugName">Xeljanz</span>;</li>
<li>
<span class="countryCode">(HK)</span> <span class="country">Hong Kong</span><span class="countrySeparator">: </span><span class="drugName">Xeljanz | Xeljanz XR</span>;</li>
<li>
<span class="countryCode">(HR)</span> <span class="country">Croatia</span><span class="countrySeparator">: </span><span class="drugName">Xeljanz</span>;</li>
<li>
<span class="countryCode">(HU)</span> <span class="country">Hungary</span><span class="countrySeparator">: </span><span class="drugName">Xeljanz</span>;</li>
<li>
<span class="countryCode">(IE)</span> <span class="country">Ireland</span><span class="countrySeparator">: </span><span class="drugName">Xeljanz</span>;</li>
<li>
<span class="countryCode">(IN)</span> <span class="country">India</span><span class="countrySeparator">: </span><span class="drugName">Aztofa | Aztofa xr | Evertop | Exnib | Exnib od | Getrid ra | Intajac | Jakauto | Jaknat | Jakseas | Jakura | Novanib t | T jaki | Tfct nib | Tnib | Tofadoz | Tofahenz | Tofajak | Tofakin | Tofakin er | Tofanta new | Tofanta xr | Tofashine | Tofashine xr | Tofatas | Tofatas xr | Tofaxen | Tofe | Tofe er | Tofza | Tonib | Tosanib | Xeljanz</span>;</li>
<li>
<span class="countryCode">(IT)</span> <span class="country">Italy</span><span class="countrySeparator">: </span><span class="drugName">Xeljanz</span>;</li>
<li>
<span class="countryCode">(JO)</span> <span class="country">Jordan</span><span class="countrySeparator">: </span><span class="drugName">Trijan | Xeljanz</span>;</li>
<li>
<span class="countryCode">(JP)</span> <span class="country">Japan</span><span class="countrySeparator">: </span><span class="drugName">Xeljanz</span>;</li>
<li>
<span class="countryCode">(KE)</span> <span class="country">Kenya</span><span class="countrySeparator">: </span><span class="drugName">Xeltin</span>;</li>
<li>
<span class="countryCode">(KR)</span> <span class="country">Korea, Republic of</span><span class="countrySeparator">: </span><span class="drugName">Xeljanz | Xeltoz</span>;</li>
<li>
<span class="countryCode">(KW)</span> <span class="country">Kuwait</span><span class="countrySeparator">: </span><span class="drugName">Xeljanz</span>;</li>
<li>
<span class="countryCode">(LB)</span> <span class="country">Lebanon</span><span class="countrySeparator">: </span><span class="drugName">Xeljanz | Xeljanz XR</span>;</li>
<li>
<span class="countryCode">(LT)</span> <span class="country">Lithuania</span><span class="countrySeparator">: </span><span class="drugName">Xeljanz</span>;</li>
<li>
<span class="countryCode">(LU)</span> <span class="country">Luxembourg</span><span class="countrySeparator">: </span><span class="drugName">Xeljanz</span>;</li>
<li>
<span class="countryCode">(LV)</span> <span class="country">Latvia</span><span class="countrySeparator">: </span><span class="drugName">Xeljanz</span>;</li>
<li>
<span class="countryCode">(MA)</span> <span class="country">Morocco</span><span class="countrySeparator">: </span><span class="drugName">Xeljanz</span>;</li>
<li>
<span class="countryCode">(MX)</span> <span class="country">Mexico</span><span class="countrySeparator">: </span><span class="drugName">Xeljanz | Xeljanz XR</span>;</li>
<li>
<span class="countryCode">(MY)</span> <span class="country">Malaysia</span><span class="countrySeparator">: </span><span class="drugName">Xeljanz</span>;</li>
<li>
<span class="countryCode">(NG)</span> <span class="country">Nigeria</span><span class="countrySeparator">: </span><span class="drugName">Xeljanz</span>;</li>
<li>
<span class="countryCode">(NL)</span> <span class="country">Netherlands</span><span class="countrySeparator">: </span><span class="drugName">Xeljanz</span>;</li>
<li>
<span class="countryCode">(NO)</span> <span class="country">Norway</span><span class="countrySeparator">: </span><span class="drugName">Xeljanz | Xeljanz XR</span>;</li>
<li>
<span class="countryCode">(NZ)</span> <span class="country">New Zealand</span><span class="countrySeparator">: </span><span class="drugName">Tofacitinib | Xeljanz</span>;</li>
<li>
<span class="countryCode">(PE)</span> <span class="country">Peru</span><span class="countrySeparator">: </span><span class="drugName">Xeljanz</span>;</li>
<li>
<span class="countryCode">(PH)</span> <span class="country">Philippines</span><span class="countrySeparator">: </span><span class="drugName">Tofacitinib | Xeljanz | Xeljanz XR</span>;</li>
<li>
<span class="countryCode">(PL)</span> <span class="country">Poland</span><span class="countrySeparator">: </span><span class="drugName">Xeljanz</span>;</li>
<li>
<span class="countryCode">(PR)</span> <span class="country">Puerto Rico</span><span class="countrySeparator">: </span><span class="drugName">Xeljanz | Xeljanz XR</span>;</li>
<li>
<span class="countryCode">(PT)</span> <span class="country">Portugal</span><span class="countrySeparator">: </span><span class="drugName">Xeljanz</span>;</li>
<li>
<span class="countryCode">(PY)</span> <span class="country">Paraguay</span><span class="countrySeparator">: </span><span class="drugName">Xeljanz</span>;</li>
<li>
<span class="countryCode">(QA)</span> <span class="country">Qatar</span><span class="countrySeparator">: </span><span class="drugName">Trijan | Xeljanz | Xeljanz XR</span>;</li>
<li>
<span class="countryCode">(RO)</span> <span class="country">Romania</span><span class="countrySeparator">: </span><span class="drugName">Xeljanz</span>;</li>
<li>
<span class="countryCode">(RU)</span> <span class="country">Russian Federation</span><span class="countrySeparator">: </span><span class="drugName">Jakvinus | Jaquinus</span>;</li>
<li>
<span class="countryCode">(SA)</span> <span class="country">Saudi Arabia</span><span class="countrySeparator">: </span><span class="drugName">Xeljanz</span>;</li>
<li>
<span class="countryCode">(SE)</span> <span class="country">Sweden</span><span class="countrySeparator">: </span><span class="drugName">Xeljanz</span>;</li>
<li>
<span class="countryCode">(SG)</span> <span class="country">Singapore</span><span class="countrySeparator">: </span><span class="drugName">Xeljanz</span>;</li>
<li>
<span class="countryCode">(SI)</span> <span class="country">Slovenia</span><span class="countrySeparator">: </span><span class="drugName">Xeljanz</span>;</li>
<li>
<span class="countryCode">(SK)</span> <span class="country">Slovakia</span><span class="countrySeparator">: </span><span class="drugName">Xeljanz</span>;</li>
<li>
<span class="countryCode">(TH)</span> <span class="country">Thailand</span><span class="countrySeparator">: </span><span class="drugName">Xeljanz</span>;</li>
<li>
<span class="countryCode">(TN)</span> <span class="country">Tunisia</span><span class="countrySeparator">: </span><span class="drugName">Xeljanz</span>;</li>
<li>
<span class="countryCode">(TR)</span> <span class="country">Turkey</span><span class="countrySeparator">: </span><span class="drugName">Xeljanz | Xeljanz XR</span>;</li>
<li>
<span class="countryCode">(TW)</span> <span class="country">Taiwan</span><span class="countrySeparator">: </span><span class="drugName">Xeljanz | Xeljanz XR</span>;</li>
<li>
<span class="countryCode">(UA)</span> <span class="country">Ukraine</span><span class="countrySeparator">: </span><span class="drugName">Xeljanz</span>;</li>
<li>
<span class="countryCode">(ZA)</span> <span class="country">South Africa</span><span class="countrySeparator">: </span><span class="drugName">Tofajak | Xeljanz | Xeljanz XR</span>;</li>
<li>
<span class="countryCode">(ZW)</span> <span class="country">Zimbabwe</span><span class="countrySeparator">: </span><span class="drugName">Xeljanz</span></li></ul></div>
</div>
</div>
</div>
</div><div class="headingAnchor" id="references"><ol id="reference">
<li>
<div class="reference" id="lexi-content-ref-USP.1">
<a name="USP.1"></a>&lt;800&gt; Hazardous Drugs—Handling in Healthcare Settings. <i>United States Pharmacopeia and National Formulary</i> (USP 40-NF 35). Rockville, MD: United States Pharmacopeia Convention; 2017:83-102.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-11487763">
<a name="11487763"></a>Ahlfors CE. Benzyl alcohol, kernicterus, and unbound bilirubin<i>. J Pediatr</i>. 2001;139(2):317-319. doi:10.1067/mpd.2001.116281<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/tofacitinib-pediatric-drug-information/abstract-text/11487763/pubmed" id="11487763" target="_blank">11487763</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-ACOG.1">
<a name="ACOG.1"></a>American College of Obstetricians and Gynecologists (ACOG). COVID-19 FAQs for obstetricians-gynecologists, obstetrics. https://www.acog.org/clinical-information/physician-faqs/covid-19-faqs-for-ob-gyns-obstetrics. Accessed December 4, 2023.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27060684">
<a name="27060684"></a>Anderson PO, Sauberan JB. Modeling drug passage into human milk. <i>Clin Pharmacol Ther</i>. 2016;100(1):42-52. doi:10.1002/cpt.377<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/tofacitinib-pediatric-drug-information/abstract-text/27060684/pubmed" id="27060684" target="_blank">27060684</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26051365">
<a name="26051365"></a>Bachelez H, van de Kerkhof PC, Strohal R, et al; OPT Compare Investigators. Tofacitinib versus etanercept or placebo in moderate-to-severe chronic plaque psoriasis: a phase 3 randomised non-inferiority trial. <i>Lancet</i>. 2015;386(9993):552-561. doi:10.1016/S0140-6736(14)62113-9<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/tofacitinib-pediatric-drug-information/abstract-text/26051365/pubmed" id="26051365" target="_blank">26051365</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Bhimraj.1">
<a name="Bhimraj.1"></a>Bhimraj A, Morgan RL, Shumaker AH, et al; Infectious Diseases Society of America. Infectious Diseases Society of America guidelines on the treatment and management of patients with COVID-19. https://www.idsociety.org/practice-guideline/covid-19-guideline-treatment-and-management/. Updated June 29, 2022. Accessed August 10, 2022.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-6810084">
<a name="6810084"></a>Centers for Disease Control and Prevention (CDC). Neonatal deaths associated with use of benzyl alcohol—United States. <i>MMWR Morb Mortal Wkly Rep</i>. 1982;31(22):290-291. <a href="https://www.cdc.gov/mmwr/preview/mmwrhtml/00001109.htm" target="_blank">http://www.cdc.gov/mmwr/preview/mmwrhtml/00001109.htm</a>.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/tofacitinib-pediatric-drug-information/abstract-text/6810084/pubmed" id="6810084" target="_blank">6810084</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27282428">
<a name="27282428"></a>Clowse ME, Feldman SR, Isaacs JD, et al. Pregnancy outcomes in the tofacitinib safety databases for rheumatoid arthritis and psoriasis. <i>Drug Saf.</i> 2016;39(8):755-762. doi:10.1007/s40264-016-0431-z<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/tofacitinib-pediatric-drug-information/abstract-text/27282428/pubmed" id="27282428" target="_blank">27282428</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-33127856">
<a name="33127856"></a>Cohen SB, Tanaka Y, Mariette X, et al. Long-term safety of tofacitinib up to 9.5 years: a comprehensive integrated analysis of the rheumatoid arthritis clinical development programme. <i>RMD Open</i>. 2020;6(3):e001395. doi:10.1136/rmdopen-2020-001395<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/tofacitinib-pediatric-drug-information/abstract-text/33127856/pubmed" id="33127856" target="_blank">33127856</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27113415">
<a name="27113415"></a>Curtis JR, Xie F, Yun H, Bernatsky S, Winthrop KL. Real-world comparative risks of herpes virus infections in tofacitinib and biologic-treated patients with rheumatoid arthritis. <i>Ann Rheum Dis</i>. 2016;75(10):1843-1847. doi:10.1136/annrheumdis-2016-209131<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/tofacitinib-pediatric-drug-information/abstract-text/27113415/pubmed" id="27113415" target="_blank">27113415</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-33752237">
<a name="33752237"></a>Desai RJ, Pawar A, Khosrow-Khavar F, Weinblatt ME, Kim SC. Risk of venous thromboembolism associated with tofacitinib in patients with rheumatoid arthritis: a population-based cohort study. <i>Rheumatology (Oxford)</i>. 2021;61(1):121-130. doi:10.1093/rheumatology/keab294<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/tofacitinib-pediatric-drug-information/abstract-text/33752237/pubmed" id="33752237" target="_blank">33752237</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30552833">
<a name="30552833"></a>Desai RJ, Pawar A, Weinblatt ME, Kim SC. Comparative risk of venous thromboembolism in rheumatoid arthritis patients receiving tofacitinib versus those receiving tumor necrosis factor inhibitors: an Observational Cohort Study.<i> Arthritis Rheumatol</i>. 2019;71(6):892-900. doi:10.1002/art.40798<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/tofacitinib-pediatric-drug-information/abstract-text/30552833/pubmed" id="30552833" target="_blank">30552833</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-35551258">
<a name="35551258"></a>Faquetti ML, Grisoni F, Schneider P, Schneider G, Burden AM. Identification of novel off targets of baricitinib and tofacitinib by machine learning with a focus on thrombosis and viral infection. <i>Sci Rep</i>. 2022;12(1):7843. doi:10.1038/s41598-022-11879-1<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/tofacitinib-pediatric-drug-information/abstract-text/35551258/pubmed" id="35551258" target="_blank">35551258</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-FDA.1">
<a name="FDA.1"></a>FDA Safety Alert. MedWatch. Xeljanz, Xeljanz XR (tofacitinib): Drug safety communication – due to an increased risk of blood clots and death with higher dose. Food and Drug Administration website. <a href="https://www.fda.gov/safety/medwatch-safety-alerts-human-medical-products/xeljanz-xeljanz-xr-tofacitinib-drug-safety-communication-due-increased-risk-blood-clots-and-death" target="_blank">https://www.fda.gov/safety/medwatch-safety-alerts-human-medical-products/xeljanz-xeljanz-xr-tofacitinib-drug-safety-communication-due-increased-risk-blood-clots-and-death</a>. Accessed August 5, 2019.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-34309233">
<a name="34309233"></a>Fernández-Sánchez M, Ribes-Artero H, Romá-Sánchez E, et al. Fetal exposure to tofacitinib during the first trimester: a healthy newborn case report. <i>Birth Defects Res</i>. 2021;113(17):1275-1279. doi:10.1002/bdr2.1942<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/tofacitinib-pediatric-drug-information/abstract-text/34309233/pubmed" id="34309233" target="_blank">34309233</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-34101387">
<a name="34101387"></a>Fraenkel L, Bathon JM, England BR, et al. 2021 American College of Rheumatology guideline for the treatment of rheumatoid arthritis. <i>Arthritis Care Res (Hoboken)</i>. 2021;73(7):924-939. doi:10.1002/acr.24596<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/tofacitinib-pediatric-drug-information/abstract-text/34101387/pubmed" id="34101387" target="_blank">34101387</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-35718887">
<a name="35718887"></a>Goodman SM, Springer BD, Chen AF, et al. 2022 American College of Rheumatology/American Association of Hip and Knee Surgeons guideline for the perioperative management of antirheumatic medication in patients with rheumatic diseases undergoing elective total hip or total knee arthroplasty. <i>Arthritis Care Res (Hoboken)</i>. 2022;74(9):1399-1408. doi:10.1002/acr.24893<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/tofacitinib-pediatric-drug-information/abstract-text/35718887/pubmed" id="35718887" target="_blank">35718887</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-34133856">
<a name="34133856"></a>Guimarães PO, Quirk D, Furtado RH, et al; STOP-COVID Trial Investigators. Tofacitinib in patients hospitalized with Covid-19 pneumonia. <i>N Engl J Med.</i> 2021;385(5):406-415. doi:10.1056/NEJMoa2101643<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/tofacitinib-pediatric-drug-information/abstract-text/34133856/pubmed" id="34133856" target="_blank">34133856</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30806708">
<a name="30806708"></a>Harigai M. Growing evidence of the safety of JAK inhibitors in patients with rheumatoid arthritis. <i>Rheumatology (Oxford)</i>. 2019;58(suppl 1):i34-i42. doi:10.1093/rheumatology/key287<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/tofacitinib-pediatric-drug-information/abstract-text/30806708/pubmed" id="30806708" target="_blank">30806708</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-35504889">
<a name="35504889"></a>Hoisnard L, Lebrun-Vignes B, Maury S, et al. Adverse events associated with JAK inhibitors in 126,815 reports from the WHO pharmacovigilance database. <i>Sci Rep</i>. 2022;12(1):7140. doi:10.1038/s41598-022-10777-w<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/tofacitinib-pediatric-drug-information/abstract-text/35504889/pubmed" id="35504889" target="_blank">35504889</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30242639">
<a name="30242639"></a>Huang F, Luo ZC. Adverse drug events associated with 5mg versus 10mg tofacitinib (Janus kinase inhibitor) twice daily for the treatment of autoimmune diseases: a systematic review and meta-analysis of randomized controlled trials. <i>Clin Rheumatol</i>. 2019;38(2):523-534. doi:10.1007/s10067-018-4299-4<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/tofacitinib-pediatric-drug-information/abstract-text/30242639/pubmed" id="30242639" target="_blank">30242639</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-9024461">
<a name="9024461"></a>"Inactive" ingredients in pharmaceutical products: update (subject review). American Academy of Pediatrics Committee on Drugs. <i>Pediatrics</i>. 1997;99(2):268-278. doi:10.1542/peds.99.2.268<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/tofacitinib-pediatric-drug-information/abstract-text/9024461/pubmed" id="9024461" target="_blank">9024461</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-10891521">
<a name="10891521"></a>Ito S. Drug therapy for breast-feeding women. <i>N Engl J Med</i>. 2000;343(2):118-126. doi:10.1056/NEJM200007133430208<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/tofacitinib-pediatric-drug-information/abstract-text/10891521/pubmed" id="10891521" target="_blank">10891521</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-35194004">
<a name="35194004"></a>Ji X, Hu L, Wang Y, Man S, et al. Risk of tuberculosis in patients with rheumatoid arthritis treated with biological and targeted drugs: meta-analysis of randomized clinical trials. <i>Chin Med J (Engl)</i>. 2022;135(4):409-415. doi:10.1097/CM9.0000000000001948<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/tofacitinib-pediatric-drug-information/abstract-text/35194004/pubmed" id="35194004" target="_blank">35194004</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-37269871">
<a name="37269871"></a>Julsgaard M, Mahadevan U, Vestergaard T, et al. Tofacitinib concentrations in plasma and breastmilk of a lactating woman with ulcerative colitis. <i>Lancet Gastroenterol Hepatol.</i> 2023;8(8):695-697. doi:10.1016/S2468-1253(23)00158-9<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/tofacitinib-pediatric-drug-information/abstract-text/37269871/pubmed" id="37269871" target="_blank">37269871</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-33080751">
<a name="33080751"></a>Kadoba K, Waki D, Nishimura K, et al. Development of severe thrombocytopenia with TAFRO syndrome-like features in a patient with rheumatoid arthritis treated with a Janus kinase inhibitor: a case report. <i>Medicine (Baltimore)</i>. 2020;99(42):e22793. doi:10.1097/MD.0000000000022793<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/tofacitinib-pediatric-drug-information/abstract-text/33080751/pubmed" id="33080751" target="_blank">33080751</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-35643956">
<a name="35643956"></a>Khosrow-Khavar F, Desai RJ, Lee H, Lee SB, Kim SC. Tofacitinib and risk of malignancy: results from the Safety of Tofacitinib in Routine Care Patients With Rheumatoid Arthritis (STAR-RA) Study. <i>Arthritis Rheumatol</i>. 2022a;74(10):1648-1659. doi:10.1002/art.42250<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/tofacitinib-pediatric-drug-information/abstract-text/35643956/pubmed" id="35643956" target="_blank">35643956</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-35027405">
<a name="35027405"></a>Khosrow-Khavar F, Kim SC, Lee H, Lee SB, Desai RJ. Tofacitinib and risk of cardiovascular outcomes: results from the Safety of TofAcitinib in Routine care patients with Rheumatoid Arthritis (STAR-RA) study. <i>Ann Rheum Dis</i>. 2022b;81(6):798-804. doi:10.1136/annrheumdis-2021-221915<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/tofacitinib-pediatric-drug-information/abstract-text/35027405/pubmed" id="35027405" target="_blank">35027405</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30177460">
<a name="30177460"></a>Kivitz AJ, Cohen S, Keystone E, et al. A pooled analysis of the safety of tofacitinib as monotherapy or in combination with background conventional synthetic disease-modifying antirheumatic drugs in a Phase 3 rheumatoid arthritis population. <i>Semin Arthritis Rheum</i>. 2018;48(3):406-415. doi:10.1016/j.semarthrit.2018.07.006<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/tofacitinib-pediatric-drug-information/abstract-text/30177460/pubmed" id="30177460" target="_blank">30177460</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-33671049">
<a name="33671049"></a>Kotyla PJ, Engelmann M, Giemza-Stokłosa J, Wnuk B, Islam MA. Thromboembolic adverse drug reactions in Janus Kinase (JAK) inhibitors: does the inhibitor specificity play a role? <i>Int J Mol Sci</i>. 2021;22(5):2449. doi:10.3390/ijms22052449<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/tofacitinib-pediatric-drug-information/abstract-text/33671049/pubmed" id="33671049" target="_blank">33671049</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-33570260">
<a name="33570260"></a>Kremer JM, Bingham CO 3rd, Cappelli LC, et al. Postapproval comparative safety study of tofacitinib and biological disease-modifying antirheumatic drugs: 5-year results from a United States-based Rheumatoid Arthritis Registry.<i> ACR Open Rheumatol</i>. 2021;3(3):173-184. doi:10.1002/acr2.11232<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/tofacitinib-pediatric-drug-information/abstract-text/33570260/pubmed" id="33570260" target="_blank">33570260</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29622655">
<a name="29622655"></a>Lam C, Ferguson ID, Mariano MC, et al. Repurposing tofacitinib as an anti-myeloma therapeutic to reverse growth-promoting effects of the bone marrow microenvironment. <i>Haematologica</i>. 2018;103(7):1218-1228. doi:10.3324/haematol.2017.174482<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/tofacitinib-pediatric-drug-information/abstract-text/29622655/pubmed" id="29622655" target="_blank">29622655</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30900375">
<a name="30900375"></a>Lee EB, Yamanaka H, Liu Y, et al. Efficacy and safety of tofacitinib for the treatment of rheumatoid arthritis in patients from the Asia-Pacific region: post-hoc analyses of pooled clinical study data. <i>Int J Rheum Dis</i>. 2019;22(6):1094-1106. doi:10.1111/1756-185X.13516<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/tofacitinib-pediatric-drug-information/abstract-text/30900375/pubmed" id="30900375" target="_blank">30900375</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-33470695">
<a name="33470695"></a>Magrì S, Chessa L, Demurtas M, Cabras F, Mocci G. Review article: safety of new biologic agents for inflammatory bowel disease in the liver. <i>Eur J Gastroenterol Hepatol</i>. 2021;33(5):623-630. doi:10.1097/MEG.0000000000002076<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/tofacitinib-pediatric-drug-information/abstract-text/33470695/pubmed" id="33470695" target="_blank">33470695</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29982686">
<a name="29982686"></a>Mahadevan U, Dubinsky MC, Su C, et al. Outcomes of pregnancies with maternal/paternal exposure in the tofacitinib safety databases for ulcerative colitis. <i>Inflamm Bowel Dis</i>. 2018;24(12):2494-2500. doi:10.1093/ibd/izy160<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/tofacitinib-pediatric-drug-information/abstract-text/29982686/pubmed" id="29982686" target="_blank">29982686</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30658060">
<a name="30658060"></a>Mahadevan U, Robinson C, Bernasko N, et al. Inflammatory bowel disease in pregnancy clinical care pathway: a report from the American Gastroenterological Association IBD Parenthood Project Working Group. <i>Gastroenterology</i>. 2019;156(5):1508-1524. doi:10.1053/j.gastro.2018.12.022<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/tofacitinib-pediatric-drug-information/abstract-text/30658060/pubmed" id="30658060" target="_blank">30658060</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28284845">
<a name="28284845"></a>Maneiro JR, Souto A, Gomez-Reino JJ. Risks of malignancies related to tofacitinib and biological drugs in rheumatoid arthritis: systematic review, meta-analysis, and network meta-analysis. <i>Semin Arthritis Rheum</i>. 201t;47(2):149-156. doi:10.1016/j.semarthrit.2017.02.007<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/tofacitinib-pediatric-drug-information/abstract-text/28284845/pubmed" id="28284845" target="_blank">28284845</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-32759265">
<a name="32759265"></a>Mease P, Charles-Schoeman C, Cohen S, et al. Incidence of venous and arterial thromboembolic events reported in the tofacitinib rheumatoid arthritis, psoriasis and psoriatic arthritis development programmes and from real-world data. <i>Ann Rheum Dis</i>. 2020;79(11):1400-1413. doi:10.1136/annrheumdis-2019-216761<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/tofacitinib-pediatric-drug-information/abstract-text/32759265/pubmed" id="32759265" target="_blank">32759265</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-32119894">
<a name="32119894"></a>Menter A, Gelfand JM, Connor C, et al. Joint American Academy of Dermatology-National Psoriasis Foundation guidelines of care for the management of psoriasis with systemic nonbiologic therapies. <i>J Am Acad Dermatol</i>. 2020;82(6):1445-1486. doi:10.1016/j.jaad.2020.02.044<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/tofacitinib-pediatric-drug-information/abstract-text/32119894/pubmed" id="32119894" target="_blank">32119894</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-NIH.1">
<a name="NIH.1"></a>National Institutes of Health (NIH). COVID-19 Treatment Guidelines Panel. Coronavirus disease 2019 (COVID-19) treatment guidelines. <a href="https://www.covid19treatmentguidelines.nih.gov/" target="_blank">https://www.covid19treatmentguidelines.nih.gov/</a>. Updated August 8, 2022. Accessed August 9, 2022.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-NIH.2">
<a name="NIH.2"></a>National Institutes of Health (NIH). COVID-19 Treatment Guidelines Panel. Coronavirus disease 2019 (COVID-19) treatment guidelines. <a href="https://www.covid19treatmentguidelines.nih.gov/" target="_blank">https://www.covid19treatmentguidelines.nih.gov/</a>. Updated April 20, 2023. Accessed May 9, 2023.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22924949">
<a name="22924949"></a>Papp KA, Menter A, Strober B, et al. Efficacy and safety of tofacitinib, an oral Janus kinase inhibitor, in the treatment of psoriasis: a Phase 2b randomized placebo-controlled dose-ranging study. <i>Br J Dermatol</i>. 2012;167(3):668-677. doi:10.1111/j.1365-2133.2012.11168.x<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/tofacitinib-pediatric-drug-information/abstract-text/22924949/pubmed" id="22924949" target="_blank">22924949</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26149717">
<a name="26149717"></a>Papp KA, Menter MA, Abe M, et al; OPT Pivotal 1 and OPT Pivotal 2 investigators. Tofacitinib, an oral Janus kinase inhibitor, for the treatment of chronic plaque psoriasis: results from two randomized, placebo-controlled, phase III trials. <i>Br J Dermatol</i>. 2015;173(4):949-961. doi:10.1111/bjd.14018<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/tofacitinib-pediatric-drug-information/abstract-text/26149717/pubmed" id="26149717" target="_blank">26149717</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28513593">
<a name="28513593"></a>Robinette ML, Cella M, Telliez JB, et al. Jak3 deficiency blocks innate lymphoid cell development. <i>Mucosal Immunol</i>. 2018;11(1):50-60. doi:10.1038/mi.2017.38<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/tofacitinib-pediatric-drug-information/abstract-text/28513593/pubmed" id="28513593" target="_blank">28513593</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-32090480">
<a name="32090480"></a>Sammaritano LR, Bermas BL, Chakravarty EE, et al. 2020 American College of Rheumatology guideline for the management of reproductive health in rheumatic and musculoskeletal diseases. <i>Arthritis Rheumatol</i>. 2020;72(4):529-556. doi:10.1002/art.41191<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/tofacitinib-pediatric-drug-information/abstract-text/32090480/pubmed" id="32090480" target="_blank">32090480</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28028154">
<a name="28028154"></a>Schulze-Koops H, Strand V, Nduaka C, et al. Analysis of haematological changes in tofacitinib-treated patients with rheumatoid arthritis across phase 3 and long-term extension studies. <i>Rheumatology (Oxford)</i>. 2017;56(1):46-57. doi:10.1093/rheumatology/kew329<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/tofacitinib-pediatric-drug-information/abstract-text/28028154/pubmed" id="28028154" target="_blank">28028154</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-33910632">
<a name="33910632"></a>Solipuram V, Mohan A, Patel R, Ni R. Effect of janus kinase inhibitors and methotrexate combination on malignancy in patients with rheumatoid arthritis: a systematic review and meta-analysis of randomized controlled trials. <i>Auto Immun Highlights</i>. 2021;12(1):8. doi:10.1186/s13317-021-00153-5<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/tofacitinib-pediatric-drug-information/abstract-text/33910632/pubmed" id="33910632" target="_blank">33910632</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-NIOSH.1">
<a name="NIOSH.1"></a>US Department of Health and Human Services; Centers for Disease Control and Prevention; National Institute for Occupational Safety and Health. NIOSH list of antineoplastic and other hazardous drugs in healthcare settings 2016. <a href="https://www.cdc.gov/niosh/docs/2016-161/default.html" target="_blank">https://www.cdc.gov/niosh/docs/2016-161/default.html</a>. Updated September 2016. Accessed October 5, 2016.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-FDA.2">
<a name="FDA.2"></a>US Food and Drug Administration (FDA). FDA Safety Alert. MedWatch. Xeljanz, Xeljanz XR (tofacitinib): FDA requires warnings about increased risk of serious heart-related events, cancer, blood clots, and death for JAK inhibitors that treat certain chronic inflammatory conditions. <a href="https://www.fda.gov/drugs/drug-safety-and-availability/fda-requires-warnings-about-increased-risk-serious-heart-related-events-cancer-blood-clots-and-death" target="_blank">https://www.fda.gov/drugs/drug-safety-and-availability/fda-requires-warnings-about-increased-risk-serious-heart-related-events-cancer-blood-clots-and-death</a>. Accessed September 2, 2021</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30427585">
<a name="30427585"></a>van Vollenhoven R, Lee EB, Strengholt S, et al. Evaluation of the short-, mid-, and long-term effects of tofacitinib on lymphocytes in patients with rheumatoid arthritis. <i>Arthritis Rheumatol</i>. 2019;71(5):685-695. doi:10.1002/art.40780<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/tofacitinib-pediatric-drug-information/abstract-text/30427585/pubmed" id="30427585" target="_blank">30427585</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24943354">
<a name="24943354"></a>Winthrop KL, Yamanaka H, Valdez H, et al. Herpes zoster and tofacitinib therapy in patients with rheumatoid arthritis. <i>Arthritis Rheumatol</i>. 2014;66(10):2675-2684. doi:10.1002/art.38745<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/tofacitinib-pediatric-drug-information/abstract-text/24943354/pubmed" id="24943354" target="_blank">24943354</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30953540">
<a name="30953540"></a>Wollenhaupt J, Lee EB, Curtis JR, et al. Safety and efficacy of tofacitinib for up to 9.5 years in the treatment of rheumatoid arthritis: final results of a global, open-label, long-term extension study. <i>Arthritis Res Ther</i>. 2019;21(1):89. doi:10.1186/s13075-019-1866-2<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/tofacitinib-pediatric-drug-information/abstract-text/30953540/pubmed" id="30953540" target="_blank">30953540</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24692527">
<a name="24692527"></a>Wollenhaupt J, Silverfield J, Lee EB, et al. Safety and efficacy of tofacitinib, an oral janus kinase inhibitor, for the treatment of rheumatoid arthritis in open-label, long term extension studies. <i>J Rheumatol</i>. 2014;41(5):837-852. doi:10.3899/jrheum.130683<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/tofacitinib-pediatric-drug-information/abstract-text/24692527/pubmed" id="24692527" target="_blank">24692527</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Xeljanz.1">
<a name="Xeljanz.1"></a>Xeljanz/Xeljanz XR (tofacitinib) [prescribing information]. New York, NY: Pfizer Inc; January 2022.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Xeljanz.2">
<a name="Xeljanz.2"></a>Xeljanz/Xeljanz XR (tofacitinib) [product monograph]. Kirkland, Quebec, Canada: Pfizer Canada ULC; May 2022.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-32906027">
<a name="32906027"></a>Xie W, Yang X, Huang H, Gao D, Ji L, Zhang Z. Risk of malignancy with non-TNFi biologic or tofacitinib therapy in rheumatoid arthritis: A meta-analysis of observational studies. <i>Semin Arthritis Rheum</i>. 2020;50(5):930-937. doi:10.1016/j.semarthrit.2020.08.007<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/tofacitinib-pediatric-drug-information/abstract-text/32906027/pubmed" id="32906027" target="_blank">32906027</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27213279">
<a name="27213279"></a>Xie F, Yun H, Bernatsky S, Curtis JR. Brief report: risk of gastrointestinal perforation among rheumatoid arthritis patients receiving tofacitinib, tocilizumab, or other biologic treatments. <i>Arthritis Rheumatol</i>. 2016;68(11):2612-2617. doi:10.1002/art.39761<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/tofacitinib-pediatric-drug-information/abstract-text/27213279/pubmed" id="27213279" target="_blank">27213279</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-35081280">
<a name="35081280"></a>Ytterberg SR, Bhatt DL, Mikuls TR, et al. Cardiovascular and cancer risk with tofacitinib in rheumatoid arthritis. <i>N Engl J Med</i>. 2022;386(4):316-326. doi:10.1056/NEJMoa2109927<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/tofacitinib-pediatric-drug-information/abstract-text/35081280/pubmed" id="35081280" target="_blank">35081280</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27905037">
<a name="27905037"></a>Zyuz'kov GN, Zhdanov VV, Udut EV, et al. Involvement of JAK1, JAK2, and JAK3 in stimulation of functional activity of mesenchymal progenitor cells by fibroblast growth factor. <i>Bull Exp Biol Med</i>. 2016;162(2):240-243. doi:10.1007/s10517-016-3585-x<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/tofacitinib-pediatric-drug-information/abstract-text/27905037/pubmed" id="27905037" target="_blank">27905037</a>]</span>
</div>
</li></ol></div><div id="topicVersionRevision">Topic 129936 Version 127.0</div></div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
